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C-erbB2 belongs to the human epidermal growth factor receptor family  that plays 
an important role in the regulation of fundamental processes such as cell growth, survival 
and differentiation.  C-erbB2 or human epidermal growth factor receptor-2 (HER2) gene 
is a proto-oncogene mapped to chromosome 17q21 and encodes a 185-kD 
transmembrane glycoprotein, designated as p185HER2, which is often simply called the 
HER2 protein or receptor. C-erbB2 is known to be overexpressed, amplified or both in 
several human malignancies, including breast cancer. Amplification of c-erbB2 gene has 
been reported to occur in 10-34% of primary breast carcinomas. Furthermore, anti-HER2 
monoclonal antibodies (Mabs) are known to inhibit the growth of tumors and human 
breast cancer cell lines overexpressing the c-erbB2 protein.  
The aim of this study is to explore the expression of c-erbB2 at the genetic and 
protein level and to correlate c-erbB2 overexpression with clinico-pathologic parameters, 
biological markers and prognosis. From 321 cases of breast cancer diagnosed at the 
Singapore General Hospital, c-erbB2 overexpression was detected by 
immunohistochemistry (IHC). Biological markers: Ki-67, iNOS, c-myc and ER and PR 
were also evaluated by IHC. Clinicopathological data was obtained from the Pathology 
Registry. Nuclear image cytometry was analysed. Follow up data were traced from 
patients’ case notes and Singapore Cancer Registry.  Survival analysis of the patients for 
evaluating the prognostic significance of c-erbB2 overexpression was performed. 
In this current study, c-erbB2 overexpression was found to be expressed higher in 
grade 3 tumors compared to grade 1 and grade 2 tumors. This study also supported a 
positive correlation between c-erbB2 expression and histologic grade of breast cancer, 
with overexpression being less frequent in grade 1 and 2 than in grade 3 carcinomas (P = 
0.017). C-erbB2 overexpressed cases showed an inverse association with ER and PR 
positivity (P = 0.001); ER positive tumors were more likely to be c-erbB2 negative than 
were ER negative tumors (74.1% versus 48.1%). When analyzing the association of 
nuclear morphometric data in relation to histopathologic parameters in the group of c-
erbB2 positive breast cancers, there was a significant difference in (a) nuclear area and 
perimeter between histological grade 3 and histologic grade 1 and 2 (P = 0.001 and P = 
0.03 respectively) and (b) nuclear perimeter between tumor size ≤  20 mm and tumor size 
> 20 mm (P = 0.046). There is significant difference in overall survival (P = 0.0166), 
between c-erbB2 positive and c-erbB2 negative cases, indicating an adverse prognosis for 
the c-erbB2 positive ones. Different combinations of tumor characteristics for possible 
additive prognostic capacities were also investigated. Node positivity, ER positivity, 
histologic grade 1 and 2 group and age at diagnosis >50 group showed diminished 
survival with regard to c-erbB2 overexpression. 
It is therefore concluded that c-erbB2 overexpression in invasive breast cancer in 
Singapore women has a similar pattern and trend as that reported in studies from other 
countries with mostly western populations. C-erbB2 overexpression is strongly associated 
with poorly differentiated breast carcinoma and inversely correlated with hormone 
receptor status. Overexpression of c-erbB2 in invasive breast cancer is associated with 
poor overall survival. Strong correlation is found in c-erbB2 expression at the genetic and 
















































1.1 Epidemiology of breast cancer 
1.1.1 Breast cancer around the world 
 Breast cancer is the second leading cause of cancer deaths in women today (after 
lung cancer) and is the most common cancer among women, excluding non-melanoma 
skin cancers. The incidence rates of breast cancer show considerable variations among 
different geographical locations. It ranges from high among women in North America, 
South America and Israel, to intermediate in much of Europe and Australia, and low in 
most of Asia (Deapen et al., 2002). In America, the breast cancer incidence rates in 
females increased from 82.6 per 100,000 person-years in 1973 to 118.1 per 100,000 
person-years in 1998 (Howe et al., 2001). Within Asia, Hong Kong has the highest breast 
cancer incidence (Leung et al., 2002). In Japan, age-standardized rate of breast cancer 
which is the leading cancer in women is 41.8 per 100,000 in 1997 (Cancer research 
group., Japan, 2002).  In Ho Chi Minh city, Vietnam, breast cancer has been reported to 
have the second highest incidence, after gastric carcinoma (Nguyen et al., 1998). Breast 
cancer is also the leading cause in women who die of cancers in Malaysia. A comparative 
study with the Singapore population showed that Singapore women presented with breast 
cancer at earlier stages with a smaller tumor size as compared to Malaysian women (Yip 
et al., 1996). 
 
1.1.2 Breast cancer in Singapore 
 Breast cancer is the commonest cancer among Singapore women for the last three 
decades. More than 90,000 persons in Singapore were diagnosed with invasive breast 
cancers from January 1968 to December 1992 (Chia et al., 2001).  The ten most common 
cancers in Singapore women during the period 1993-1997 and 1998-1999 are listed in 
Table 1 (Chia et al., 2002). 
 
Table 1 Ten most frequent cancers in Singapore women (adapted from Chia KS et al., 





Breast 1 1 
Colorectum 2 2 
Lung 3 3 
Cervix 4 4 
Stomach 5 5 
Ovary 6 6 
Skin (including Melanoma) 7 7 
Corpus uteri 8 8 
Thyroid 9 9 
Lymphoma - 10 
Nasopharynx 10 - 
 
There were  20.2 breast cancer cases per 100,000 women in the period 1968-1972, 
which has increased to  38.8 per 100,000 in 1988-1992, leading to an average annual 
increase of 3.6% over the past 25-year period for all women (Seow et al., 1996). The 
incidence rate of breast cancer has increased 2.3 times in 1993-1997 compared to that in 
1968-1972 with the peak incidence age group being 45-49 years. Breast cancer comprises 
22.8% of all cancers in Singapore women and is associated with an annual mortality rate 
of 13.7 per 100,000 per year (Chia et al., 2000). The age-standardized incidence rate is 
53.1 cases per 100,000 women per year over the period of 1998-1999 as compared with 
46.1 cases per 100,000 women over the period of 1993-1997 (Chia et al., 2002). 
However, the incidence is less than 50% compared to that of American women i.e., 114.5 
per 100,000 women per year (Wingo et al., 1998).  The pattern of breast cancer incidence 
is also becoming more similar to the western population as evidenced by the shift of the 
peak age-specific incidence for breast cancer from premenopausal to postmenopausal 
years over the period of 1998-1999 (Chia et al., 2002). Among ethnic groups, there is 
controversy in different studies. Malay women have been reported to be at an increased 
risk (4.4%) of developing breast cancer as compared to Chinese and Indian women 
(1.4%) (Seow et al., 1996). In another study, Chinese women appear to be at an increased 




1.2 Classification of breast disorders 
1.2.1 Benign breast disease 
 Breast lesions are broadly classified as inflammatory, benign and malignant 
lesions. Benign breast disorders are a heterogeneous group of lesions that clinically and 
radiographically span the entire spectrum of breast abnormalities. Some benign breast 
lesions may mimic breast cancer on physical examination and imaging studies. 
Inflammatory and benign lesions are shown combined in Table 2. Categorization of 




Table 2 Categorization of benign breast lesions (modified from Schnitt et al., 2000)  
Reactive and Inflammatory 
Mammary duct ectasia 
Fat Necrosis 




            Infections 




            Cysts 
            Papillary apocrine change 




            Moderate or florid ductal hyperplasia 
            Intraductal papilloma 




            Atypical ductal hyperplasia (ADH) 










Granular cell tumors 
Fibromatosis 
Miscellaneous, like apocrine changes, calcifications. 
 
 
1.2.2 Malignant breast disease (Histologic subtypes) 
 Breast carcinoma presents in a great variety of histological patterns, including 
specific types which have useful clinical correlates and prognostic implications. 
Morphological classification of invasive breast carcinoma has existed for several 
decades. The classification system currently followed is based on a descriptive 
terminology for patterns of tumor growth (histological typing) which has been outlined 
by the World Health Organization (WHO) (Azzopardi et al., 1981). Table 3 shows the 
classification of malignant breast disease modified from that described by Page and 



















    Non-invasive 
 
Ductal carcinoma in situ 
Microinvasive carcinoma 
Lobular carcinoma in situ 
 
    Invasive 
 









     Secretory  
     Adenoid cystic  
     Mucoepidermoid  
     Invasive papillary 
     Tubulolobular 
      Inflammatory 
Rare types 
      Signet ring 
      Lipid rich 
      Clear cell 
      Myoepithelioma 













1.2.2.1 Ductal carcinoma in situ (DCIS) 
 Ductal carcinoma in situ (DCIS) originates from the terminal duct-lobular unit 
(TDLU), and implies malignant transformation of lining epithelial cells restricted within 
the basement membrane. Myoepithelial cells are seen in DCIS, which is a distinct feature 
that differentiates it from invasive carcinoma. The recognition of DCIS as a separate 
entity distinct from hyperplasia and invasive carcinoma was gradual through the first half 
of the twentieth century. It is now a firmly accepted entity, and has been categorized into 
several architectural patterns (Page and Anderson, 1987). DCIS is an early, noninvasive 
phase of breast cancer, and also the purported forerunner of the majority of invasive 
breast cancers (Frykberg and Bland, 1994). DCIS is classified into subtypes based on 
architectural patterns viz., comedo, cribriform, micropapillary, papillary, solid types. 
Currently this morphologic classification system is replaced by schemes that attempt to 
predict the biologic potential of DCIS, particularly the risk of recurrence and likelihood 
of progression to invasive carcinoma (Shoker and Sloane, 1999; Ellis et al., 1998). After 
the introduction of mammography, which has enabled early diagnosis of breast cancer, 
DCIS detection has increased from 0.8% - 5% (Tan et al., 1999; Schnitt et al., 1988) to 
15% - 20% (Lagios, 1990). In the Singapore breast screening project, it accounted for 
25% of all screen detected breast cancers (Tan et al., 1999). 
1.2.2.2 Lobular carcinoma in situ (LCIS) 
Lobular carcinoma in situ (LCIS) is a distinct entity from DCIS. It is 
predominantly a disease of premenopausal women between the ages of 40 to 50 years 
(Lishman and Lakhani, 1999). It is not clinically palpable and there are usually no 
mammographic changes. The pathological diagnosis of LCIS is made when there is a 
monomorphic population of small round cells with thin cytoplasmic rims and high 
nuclear-cytoplasmic ratios, sometimes with intracytoplasmic lumina, affecting the lobular 
units (Lishman and Lakhani, 1999). It is now regarded as risk indicator, rather than as a 
true forerunner of invasive breast cancer. Low nuclear grade solid DCIS may mimic 
LCIS, and pose diagnostic difficulty. The relationship between DCIS, LCIS and invasive 
breast cancer needs further elucidation.  
1.2.2.3 Invasive ductal carcinoma (IDC) 
 Invasive ductal carcinoma (IDC) is the most common type of invasive carcinoma 
of the breast, although exact figures derived from different publications vary. Table 4 
shows the relative percentage of main pathological types of invasive breast cancer in 
different studies. The distribution of IDC ranges from 47% to 79.2% of all subtypes of 
invasive breast cancers (Li et al., 2003; Chia et al., 2000; Pereira et al., 1995; Ellis et al., 











































Ductal 79.2 50 47 42.3 66.8 
Lobular 4.4 15.4 15 22.1 9.8 
Medullary 1.2 2.8 7.3 8.7 4.6 
Tubular 0.6 2.4 2.3 4 7.9 
Mucinous 2.6 0.9 0.9 15.4 1.7 
Cribriform 0.7 0.8 0.8 4 3.3 
Papillary 1 0.3 - 2.7 1 
Mixed 0.8 19.8 20.8 0.8 - 
Others 9.5 8.4 5.9 - 4.9 
 
 Histologically, an extreme variety of patterns without the usual regularity and 
uniformity is seen in IDC. Features of single cell infiltration, poorly cohesive islands of 
infiltrating cells, foci of poorly formed glands, or even well defined glandular patterns are 
seen throughout a single lesion. Because of this, the term “Carcinoma-No special type” 
(NST) has been used as a substitute (Dixon et al., 1985). 
 IDC usually presents as a hard, palpable mass with an average size of 2 to 3 cm, 
but the size may vary from a tiny lesion of few millimeters to as large as to replace the 
entire breast. Macroscopically, IDC is usually whitish gray in color and of varying shapes 
like stellate, oval or sometimes irregular. The typical appearance of spicules radiating out 
from the central mass lesion is characteristic of cancer which literally means ‘the crab’. 
Microscopically, there are not many distinctive features, as IDC may be solid and highly 
cellular or paucicellular (Sharkey et al., 1996).  
1.2.2.4 Invasive lobular carcinoma (ILC) 
 It is the second most frequent form of invasive breast carcinoma and accounts for 
4.5% to 15% of all invasive breast cancers (Li et al., 2003; Chia et al., 2000; Pereira et 
al., 1995; Ellis et al., 1992; Dixon et al., 1985). The incidence rate of ILC has continued 
to rise in the past 15 years (Li et al., 2003). ILC presents as a diffuse lesion that is not 
detectable by routine physical examination or by mammography. Histologically, ILC 
comprises uniform, small, round, poorly cohesive cells with rounded or oval nuclei and 
eccentrically placed cytoplasm, frequently containing intracytoplasmic lumina (du Toit et 
al., 1989). Tumor cells are arranged like narrow cords (“Indian file” pattern) in a 
desmoplastic stroma. Several subtypes or variants of invasive lobular carcinoma have 
been described: (a) classical variant (b) solid variant (c) alveolar variant (d) tubulo-
lobular variant (e) pleomorphic variant and  (f) mixed variant (Sloane et al., 1995; du Toit 
et al., 1989; Dixon et al., 1982).  
1.2.2.5 Other forms of breast carcinoma 
 These tumors are much less common than IDC or ILC and are called special 
forms due to the following reasons: (i) Specific architectural patterns, for example 
mucinous, medullary, tubular, adenoid cystic, apocrine and cribriform (ii) Distinct 
clinical behavior, for example inflammatory, metaplastic, Paget’s disease of nipple, the 
former two entities having aggressive behavior. Other than these types, a few rare forms 
of invasive breast cancers can also occur viz., pseudosarcomatous type, signet-ring cell 
type, invasive papillary, secretory carcinoma, etc. 
 Primary sarcomas of the breast are rare.  Yet the parenchyma and connective 
tissue elements are capable of giving rise to many soft tissue sarcomas. Malignant 
cystosarcoma phyllodes, a special type of sarcoma, is the most common of all. Other 
sarcomas that do arise from breast tissue are angiosarcoma, fibrosarcoma, liposarcoma, 
malignant fibrohistiocytoma etc. 
 Studies have shown that recognition of the histological type can provide highly 
significant prognostic prediction.  The special types (tubular, invasive cribriform, 
mucinous) and tubulo-lobular carcinoma carry an excellent prognosis, mixed types have 
good prognosis, classical lobular and medullary (all types) have an average prognosis; 
solid lobular and ductal (NST) types are of relatively poor prognosis (Ellis et al., 1992).   
 
1.3 Clinicopathological parameters 
1.3.1 Histologic grade 
 Histologic grading is one of the most important pathologic parameters and an 
essential determinant of prognosis that also allows risk stratification of invasive breast 
carcinoma (Fitzgibbons et al., 2000; Brown et al., 1993).  Sloane et al (1995) 
demonstrated the latest revised system of histologic grading of breast cancers. The 
histologic grading system gained its importance from the early quarter of the 20th century 
and has been well recognised by Scarff-Bloom-Richardson (1957), further modified by 
Elston and Ellis (1991) in the Nottingham study. The histological grading of breast 
cancer always has a potentially subjective element, but reproducibility can be achieved 
when specific guidelines are followed (Dalton et al., 1994; Elston and Ellis, 1991).  
 Table 5 shows the grading criteria as outlined by the Nottingham group, which 
represent a semi-quantitative modification of the Bloom and Richardson criteria, 
therefore providing more specific guidelines for grading. 
 Table 5 Criteria for histological grading of invasive breast cancer* 
Feature Score 
Degree of tubule formation 
     Majority of tumor (>75%) 
     Moderate (10-75%) 






     Small, regular uniform cells 
     Moderate increase in size and variability 










           *Elston and Ellis, 1991 
 Histologic grade is then allocated on the following basis: 
 3-5 points: grade I -- well differentiated 
 6-7 points: grade II -- moderately differentiated 
 8-9 points: grade III -- poorly differentiated 
  
 Histologic grading combines details of cell morphology (nuclear pleomorphism) 
with measurement of differentiation (tubule formation) and an assessment of proliferation 
(mitotic frequency). It is likely that histologic grade provides a sketch of a number of 
molecular events which are reflected in histological morphology (Elston and Ellis, 1991). 
Prognostic index (PI) can be calculated, if histologic grade, tumor size and lymph node 
status are known.  
 
1.3.2 Pathological staging 
 Pathological staging is an essential component of the pathologic assessment and 
one of the predictors of behavior of invasive breast carcinomas. Staging of a breast 
cancer reflects the anatomic extent of the tumor either at the time of diagnosis prior to 
treatment based on clinical, diagnostic, and biopsy information or at post-surgical 
resection when all pathologic information obtained from the resected specimen is used 
(Beahrs, 1984). Several schemes have been suggested for staging breast cancer; 
American Joint Committee on Cancer (AJCC) jointly with the TNM Committee of the 
International Union against Cancer (UICC), AJCC-TNM classification, is the currently 
recommended staging system which was adopted in 1989 (Spiessl et al., 1989), followed 
the same in 1997 (Hermanek et al., 1997) and revised in 2002 (Singletary et al., 2002). 
Staging is based on characteristics of the primary tumor (T), extent of regional axillary 
node metastases (N) and distant metastases (M). The designation TNM has been chosen 
for clinical classification and pTNM refers to pathologic staging. Pathological staging is 
more accurate than clinical staging because it does not overestimate the size of the 
primary tumor and accurately assesses the axillary lymph nodes for metastatic carcinoma 
(Rosen et al., 1975). Recommendations were made to include histologic grade into the 
revision of the TNM staging system (Yarbro et al., 1999). This does not affect the 
treatment decisions in case of larger tumors (T3 and T4) but is definitely of great value 
for small (T1 and T2) node-negative tumors. However, the latest update on the AJCC-
TNM classification has not incorporated histologic grade (Singletary et al., 2002). Studies 
show that even multicentricity does not increase the risk of poor outcomes in patients 
with early-stage breast cancer, supporting the current staging system that tumor size 
should be based on the diameter of the largest lesion in patients with multicentric breast 
cancer (Vlastos et al., 2000). The guidelines for staging are outlined in the Table 6. 
 
Table 6 AJCC - TNM staging of breast carcinomaa 
Stage 0 Tis N0 M0 


































Stage IV Any T Any N M1 
aThe original source for this material is the AJCC Cancer Staging Manual, 
Sixth Edition (2002) published by Springer-Verlag New York, USA. 
*T1 includes T1micrometastasis. 
 
1.3.3 Lymph node status 
 The pathologic status of the axillary nodes is considered one of the most 
important prognostic factors for patients with breast cancer and has repeatedly been 
shown to be the single most important predictor of disease-free survival (DFS) and 
overall survival (OS) in breast cancer (Fitzgibbons et al., 2000; Sjogrens et al., 1998; 
Ceccarelli et al., 1995; Mittra et al., 1995). The absolute number of involved nodes is also 
of prognostic importance; patients with 4 or more involved nodes have a worse prognosis 
than those with fewer than 4 involved nodes. Seventy percent of patients with lymph 
node metastasis will develop recurrences within 10 years, compared with 20% to 30% of 
node-negative patients (Fitzgibbons et al., 2000). Nodal metastasis is a critical factor in 
deciding the role of axillary lymph node dissection (Whitten et al., 1997). Recently, 
sentinel lymph node biopsy has transpired quickly as a probable alternative to axillary 
dissection and is sensitive and specific in predicting axillary node status (Krag et al., 
1998). Even after development of so many predictors and prognosticators of breast 
carcinoma, nothing can replace the position of axillary lymph node status in deciding the 
outcome of the breast cancers. Systemic adjuvant therapy depends on axillary lymph 
node metastasis and lymph node positivity is still regarded as a standard indication for it 
(Lindahl et al., 2000). 
 
1.3.4 Hormone receptors: estrogen receptor (ER) and progesterone receptor (PR) 
 Estrogen and progesterone receptor detection are established procedures in the 
routine management of patients with breast cancer for the past 2 decades. Hormonal 
receptors act primarily as predictors for response to therapeutic and adjuvant hormonal 
therapy as well as the likelihood of recurrence and as a marker of survival (Li et al., 
2003; Fitzgibbons et al., 2000) 
  Estrogen receptor (ER) is a member of a superfamily of nuclear receptors that 
includes the steroid hormone, thyroid hormone, vitamin D and retinoic acid receptors. ER 
binds estrogens which are steroid hormones that play important roles in the growth and 
development of the mammary gland; estrogens are also thought to significantly 
contribute to breast carcinogenesis (Lin et al., 2003; Hansen and Fuqua, 1999). The 
proliferative effects of estrogens are mediated through ER, which is an intracellular 
receptor.  The function of ER is relatively simple, once estrogen passes through the cell 
membrane and binds to ER, the receptor is transformed into an active transcription factor, 
binding DNA as a dimer at specific estrogen response elements (ERE’s), regulating the 
expression of a variety of genes. The activity of transcription factors is regulated by 
phosphorylation and dephosphorylation, which involves various signal transduction 
pathways (Fig 1).  









Fig. 1 Mechanism of action of estrogen (E) in human breast cancer cells. ER, estrogen 
receptor; E, estrogen; PR, progesterone receptor; GFR, growth factor receptor. 
 
  
 Progesterone receptor (PR) is also expressed in many breast cancers and plays a 
major role in breast growth, function and development. There is also in vitro evidence 
that progesterone can induce cellular differentiation (Lin et al., 2003).  PR is a protein 
induced by the action of estrogen on ER positive breast epithelial cells and whose 
synthesis is positively regulated by ER, therefore presence of PR may indicate a 
functionally intact ER response pathway (Fig 1). Therefore, tumors expressing both ER 
and PR are expected to have higher response rates for anti-estrogen and other endocrine 
therapies (Horwitz et al., 1975). Factors that increase cell proliferation in a tissue can 
result in malignant transformation by increasing the probability of converting DNA 
damage into stable mutations. Studies have been shown that both ER and PR play a role 
in breast cell proliferation during various phases of the menstrual cycle. 
 In general, women with ER-negative tumors have early recurrence, poor response 
to endocrine therapy and reduced survival compared to ER-positive tumors. ER negative 
and ER-/PR- breast tumors have an 8% to 35% lower 5 year survival rate compared with 
women with ER positive tumors (Li et al., 2003). ER positive tumors are predominantly 
Stage I and Grade 1 or 2 tumors while ER negative tumors are vice versa, confirming its 
prognostic significance (Chu et al., 2001). 
 
1.4 Biological markers 
1.4.1 Ki-67 
 Cell proliferation is indispensable for normal growth and development of the 
breast and for all tissues of the human body. Recently, various factors have been found 
which play major roles in cell proliferation. One commonly encountered cell proliferation 
factor is Ki-67, also known as MIB-1 (a monoclonal antibody), Ki-67 is one of the most 
important proapoptotic gene products (Midulla et al., 2002), that is specific for a nuclear 
antigen expressed only in G1 and S phases of  proliferating cells (Gerdes et al., 1983). 
Several studies investigated the prognostic significance of Ki-67 staining and most found 
a positive correlation with clinical parameters like tumor size, histologic grade, vascular 
invasion, axillary lymph node status, ploidy; while there was a negative correlation with 
steroid receptors (Jeziorski et al., 2000; Gasparini et al., 1989; Charpin et al., 1988; 
Walker et al., 1988). Ki-67 is also a significant prognostic determinant of disease-free 
survival in invasive breast carcinoma (Imamura et al., 1999; Midulla et al., 1999). Ki-67 
in combination with S-phase fraction is a predictor of disease recurrence (Brown et al., 
1994). MIB-1 and polyclonal Ki-67 are the best proliferation markers in conventional 




 Nitric oxide (NO) is a multi-functional messenger molecule derived from the 
amino acid L-arginine in a reaction catalyzed by three different isoforms of nitric oxide 
synthases (NOS) (Tschugguel et al., 1999). An inducible, calcium independent isoform of 
nitric oxide synthase (iNOS) is expressed in macrophages, neutrophils, endothelium and 
epithelium when stimulated appropriately (Knowles et al., 1994; Robbins et al., 1994). 
NO, which is very important in angiogenesis associated with tissue healing (Konturek et 
al., 1993), plays a dual role in tumorigenicity so that when it is produced at high 
concentrations, NO has anti-tumor activity but at lower concentrations, promotes tumor 
growth. This has been well documented in the literature (Jenkins et al., 1995; Xie et al., 
1995a; Xie et al., 1995b). However, this dual effect of NO related to the inducible 
isoform of nitric oxide synthase (iNOS) is still controversial and investigation continues 
(Tschugguel et al., 1999). The effects of NO are diverse and difficult to enumerate. 
During initiation of tumor growth, natural killer cells and macrophages kill tumor cells by 
hydroxyl (OH-) mediated mechanisms. However, NO may also suppress anti-tumor 
defense, promote tumor angiogenesis and blood flow in the tumor neovasculature and 
enhance tumor growth, invasion and metastasis (Lala et al., 1998). NO is both pro- and 
anti-apoptotic. The proapoptotic effects are predominantly due to iNOS stimulation that 
leads to accumulation of tumor suppressor protein p53, caspase activation, chromatin 
condensation and DNA fragmentation (Brune et al., 1998; Ambs et al., 1997; Dimmeler 
et al., 1997). 
 
1.4.3 C-myc  
 Deregulation of the c-myc proto-oncogene by amplification or rearrangement is 
believed to play an important role in the genesis and progression of a variety of tumors 
(Mariani-Costantini et al., 1998). It is a transcription factor involved in the regulation of a 
host of cellular activities including proliferation, differentiation, as well as apoptosis 
(Brenner and Aldaz, 1997; Escot et al., 1986). Amplification of c-myc has also been 
detected in primary breast cancers and breast cancer cell lines (Walker et al., 1989). The 
MYC gene is located on chromosome 8q24, and is amplified in approximately 20% to 
30% of breast cancers (Bergstein, 1999). The c-myc oncogene encodes a protein of 
62,000 daltons called p62, which is in the nucleus of the cell (Eisenman et al., 1985). It 
plays a role in tumor promotion by virtue of demonstrated associations between MYC 
amplification and certain clinico-pathological features like large tumor size and high 
tumor grade as well as poor survival (Brenner and Aldaz, 1997; Varley et al., 1987). It 
contributes to the development of tumors in transgenic mice carrying activated mouse 
mammary tumor virus/c-myc fusion genes (Stewart et al., 1984). There is a significant 
correlation between c-myc and c-erbB2 gene amplification in breast carcinomas (Varley 
et al., 1987). C-myc oncogene expression at various levels can be detected easily 
nowadays i.e., gene amplification by fluorescent in situ hybridization and protein 
expression by immunohistochemistry. 
 
1.4.4 C-erbB2 and epidermal growth factor receptor (EGFR) 
 The regulation of normal breast development is dependent on several hormones. 
Among these, estrogens are the best characterized and they perform an essential role in 
the control of normal mammary development and in the etiology and progression of 
breast cancer. In addition, breast epithelial cells synthesize locally acting growth factors 
that act by various pathways. The epidermal growth factor (EGF)-family of peptides, in 
combination with their cognate receptors, is significantly involved in the regulation of 
mammary gland growth, development, differentiation, morphogenesis and lactation. It 
also plays a pivotal role in the pathogenesis of human breast cancer (Normanno et al., 
1997; Oka et al., 1988). They mediate their effects by means of the human epidermal 
growth receptor family (HER or erbB Type I). This family comprises four homologous 
epidermal growth factor receptors: HER1 (EGFR/erbB1), HER2 (erbB2), HER3 (erbB3) 
and HER4 (erbB4). These are transmembrane glycoproteins, containing an extracellular 
ligand binding domain, a transmembrane lipophilic segment and an intracellular protein 
kinase domain with a carboxyl terminal segment containing sites of phosphorylation or 
tyrosine residues (van der Geer et al., 1994).  The HER family plays an important role in 
regulating cell growth, survival and differentiation in a complex manner; various ligands 
have been identified that activate individual HER receptors.  
 Many primary human tumors and human cancer cell lines express high levels of 
growth factor receptors and are capable of producing the relevant growth factors. 
Transforming growth factor-α (TGF-α), transforming growth factor-β (TGF-β), IGF-1, 
membrane receptors for prolactin and insulin, cripto-1 (CR-1) and amphiregulin (AR) are 
some of the growth receptors other than the HER family that have been identified as 
being involved in the development of breast cancer.  
 Among these, the best studied is that constituted by the erbB tyrosine kinase 
receptors (also known as type I receptor tyrosine kinases) (van der Geer et al., 1994). C-
erbB2 or human epidermal growth factor receptor-2 (HER2) gene is a proto-oncogene 
mapped to chromosome 17q21 (Popescu et al., 1989; Coussens et al., 1985). C-erbB2 
belongs to the human epidermal growth factor receptor family (HER2 or Type I trans-
membrane tyrosine kinase receptor) (Hung and Lau, 1999; Akiyama et al., 1986), that 
plays an important role in the regulation of fundamental processes such as cell growth, 
survival and differentiation. C-erbB2 is often referred to as HER2/neu in the literature; as 
the c-erbB2 gene has a high degree of homology with the rodent gene neu. The neu gene 
was first identified in rats as a proto-oncogene which was activated by mutation in 
neuroectodermal tumors (Padhy et al., 1982; Shih et al., 1981). C-erbB2 gene encodes a 
185-kD transmembrane glycoprotein, designated as p185HER2, which is often simply 
called the HER2 protein or receptor (Akiyama et al., 1986; Bargmann et al., 1986; 
Coussens et al., 1985). When inactive, HER2 receptor exists in the monomer form; once 
activated, it becomes a dimer. Dimerisation can occur between the same receptor (a 
homodimer) or between other members of the HER family (heterodimer) (Alroy and 
Yarden, 1997; Lemmon and Schlessinger 1994). C-erbB2, which is the preferred 
heterodimerisation partner within the family (Graus-Porta et al., 1997), can also be 
transactivated by EGF-like ligands and neuregulins forming HER1/HER2, HER2/HER3 
and HER2/HER4 heterodimers very easily (Baly et al., 1997; Burden and Yarden, 1997; 
Pinkas-Kramarski et al., 1997). There is no known ligand which binds C-erbB2 with high 
affinity. However, the kinase activity of c-erbB2 can be activated, if it is overexpressed 
or by hetero-association with other members of the c-erbB2 family or with EGF-like 
ligands. These ligands include EGF, transforming growth factor alpha (TGF-α), 
amphiregulin, heparin binding EGF, betacellulin and epiregulin (Pinkas-Kramarski et al., 
1997).  
 A ligand binding to a heterodimer complex containing HER2 protein on the cell 
surface leads to activation of intrinsic protein tyrosine kinase activity and tyrosine 
autophosphorylation occurs. This triggers a cascade of events that results in the 
transmission of signals across the cell membrane and across the intracellular space to the 
nucleus where gene activation subsequently occurs and leads to mitogenic stimulation 
(Alroy and Yarden 1997) (Fig 2). Thus c-erbB2 plays a key role in the cellular growth 
factor signal transduction pathway and is central in controlling normal cell growth and 
division (Akiyama et al., 1986; Scott et al., 1991) 
 
Growth factor  
 
 
Fig. 2  Steps involved in growth factor (c-erbB2) signal transduction.  
 
1.4.4.1 C-erbB2 and breast cancer 
 C-erbB2 is known to be overexpressed, amplified or both in several human 
malignancies, including breast cancer. Many animal and in vitro studies have shown that 
c-erbB2 gene amplification or protein overexpression plays a pivotal role in oncogenic 
transformation, tumorigenesis and metastasis (Dowsett et al., 2000). Amplification of c-
erbB2 gene has been reported to occur in 10-34% of primary breast carcinomas (Cho et 
al., 2003; Konigshoff et al., 2003; Hoff et al., 2002; Ross and Fletcher, 1998; 
Chariyalertsak et al., 1996; Odagiri et al., 1994; Slamon et al., 1989; Slamon et al., 1987). 
Furthermore, anti-HER2 monoclonal antibodies (Mabs) are known to inhibit the growth 
of tumors and human breast cancer cell lines overexpressing the c-erbB2 protein (Baselga 
et al., 1996; Harwerth et al., 1993). 
 Numerous studies have shown that a positive c-erbB2 status was an independent 












Gene activation          cell division  
overexpression plays a pivotal role as a prognostic marker by itself and in correlation 
with other markers (Yokota et al., 1999; Ceccarelli et al., 1995). Positive c-erbB2 status 
is generally associated with more aggressive disease leading to shortened disease free 
survival (DFS) and overall survival (OS) when compared with patients bearing c-erbB2 
negative tumors (Agrup et al., 2000; Sjogren et al., 1998; Mittra et al., 1995). It has also 
been suggested that c-erbB2 status affects survival after adjuvant chemotherapy and risk 
of locoregional recurrence. Moreover, c-erbB2 overexpression has been reported to 
induce chemoresistance under certain experimental conditions (Agrup et al., 2000; Hung 
and Lau 1999). 
 
1.4.4.2 Detection of c-erbB2 
 Many techniques have been developed and used to determine c-erbB2 status. 
Various target molecules related to c-erbB2 amplification/overexpression, i.e., DNA, 
mRNA and receptor protein, can be used in different assays (Dowsett et al., 2000). 
Quantitative assay methods such as Southern blotting (which measures gene copy 
number), Northern blotting (mRNA values) and Western blotting (protein concentrations) 
are the predominant methods  that have been used in many studies together with solid 
matrix-blotting, enzyme immunoassay (EIA) and enzyme-linked immunosorption assay 
(ELISA). These molecular techniques are limited or have failed due to several reasons: (i) 
insensitivity to low levels of gene amplification (ii) fairly large amount of fresh tissue is 
required and (iii) generally more useful as a research tool, being not practical for use in 
the routine diagnostic surgical pathology laboratory (Lian and Tan, 2002). The two main 
types of assays predominantly used nowadays are immunohistochemistry (IHC), which 
detects oncoprotein overexpression in cells; fluorescence in situ hybridization (FISH), 
which measures gene amplification/copy numbers within the tumor cells. 
 FISH detection of c-erbB2 (HER2/neu) gene amplification has been developed for 
diagnostic use in breast cancer (Press et al., 1997; Ratcliffe et al., 1997). FISH is a 
powerful molecular cytogenetic method based on the hybridization of specific DNA 
sequences to the target genome, involving both histochemical and solid matrix 
hybridization techniques (Pauletti and Slamon, 1999). A permeabilization step is required 
to facilitate penetration of the fluorescent labeled probe and a denaturation step is 
necessary for converting double stranded DNA in tissue sections to single stranded DNA 
to allow for reannealing of the probe and target genome. FISH has several advantages 
such as being highly sensitive and specific; allowing standardized, more reproducible, 
consistent results; and the ability to work on small samples. It has been approved for use 
in the United States to measure c-erbB2 (HER2/neu) gene amplification in the prognostic 
assessment of node-negative breast cancer patients who are at risk of recurrent disease 
(Dowsett et al., 2000). However, there are minor disadvantages like being relatively time 
consuming, needing skilful personnel and potentially complicated to perform.  
 IHC has been specifically adapted for detection of c-erbB2 protein using specific 
antibodies (Slamon et al., 1989; van de Vijver et al., 1988). It is the most widely used and 
practical assay available at present for assessment of c-erbB2 status. It is specific, rapid, 
requires few reagents and can be done routinely. Using IHC on paraffin sections, it has 
been shown that tumors with c-erbB2 (HER2/neu) gene amplification show strong 
membranous staining of tumor cells and vice versa. The variability in results of c-erbB2 
immunostaining is partly related to use of different anti-HER2/neu antibodies as these 
antibodies may differ in binding affinity, epitope specificity and/or cross-reactivity with 
non-HER2/neu proteins (Press et al., 1994). In many ways IHC can probably be 
considered the most appropriate assay for routine c-erbB2 testing if laboratories follow 
standardized procedures and adopt appropriate quality controls. 
 The HercepTest is the FDA-approved commercially available kit system (Dako, 
1999). It uses an arbitrary scoring system to grade the degree of membrane staining. This 
HercepTest scoring method is recommended for tumors assessed using other IHC 
methods by the United Kingdom reference laboratory group. Recently a study showed a 
high level (97%) of inter-laboratory agreement in assessing c-erbB2 status based on IHC 
assays using the same primary antibody but different detection systems (Jacobs et al., 
2000). 
1.4.4.3 C-erbB2 and treatment 
In the battle against breast cancer, researchers over the years have focused on that 
particular substance within the tumor cell carrying the descriptive name of HER2/neu 
(which is c-erbB2). Interest in c-erbB2 (HER2/neu) has waxed and waned over time. 
Researchers first speculated that excess amounts in tumor cells could predict how 
aggressively a tumor would behave, but then most discounted that notion. Researchers 
are now taking a second look at c-erbB2 after recent studies suggested that, rather than 
predicting aggressiveness, c-erbB2 may play a role in determining chemoresistance.  
There are numerous studies evaluating the predictive value of c-erbB2 status in 
relation to response to various therapies. For hormonal therapy, there is ample evidence 
suggesting the relation between c-erbB2 positivity and hormone resistance. When normal 
breast cancer cells are transfected with the c-erbB2 gene, converting them to c-erbB2 
overexpressing cells, they acquire estrogen-independent growth that is insensitive to both 
estrogen and as well as tamoxifen (anti-estrogen) (Kobayashi et al., 2002; Pietras et al., 
1995; Benz et al., 1992). C-erbB2 overexpressing breast cancer patients profited 
significantly more from aggressive, dose-intensive chemotherapy with 
cyclophosphamide, doxorubicin and 5-fluorouracil compared with c-erbB2 negative 
patients (Lehr et al., 2001). Several studies have indicated that a positive c-erbB2 status 
may predict a relative resistance to CMF (cyclophosphamide, methotrexate, 5-
fluorouracil) (Dowsett M., 2000; Gancberg et al., 2000; Mass, 2000). The relationship 
between c-erbB2 status and response to other forms of therapy besides hormonal and 
anthracycline-based chemotherapy has been investigated in a number of other studies, but 
the results are not as yet authoritative (Menard et al., 1999; Baselga et al., 1998; Benz et 
al., 1992).  
Increasing awareness is being given to the c-erbB2 receptor as a direct target for 
therapy in c-erbB2 overexpressing breast cancer for the past few years. One such 
approach is anti-HER2 monoclonal antibody therapy with trastuzumab (Herceptin®), for 
which it is an absolute requirement to determine the c-erbB2 overexpression prior to the 
initiation of therapy. C-erbB2 overexpression in invasive breast cancer has also been 
utilized in radionucleotide imaging; Allan et al (1994) used technetium 99m-labeled 
monoclonal antibodies to c-erbB2 and this approach may help antibody-targeted 




1.5 Scope of study 
 Considerable attention has been directed at identification of prognostic factors in 
breast cancer patients so that they may provide more useful information on the clinical 
outcome, allowing more appropriate individualization of therapy (Tsutsui et al., 2003). 
Activation of c-erbB2 protein results in the interaction with many different cellular 
proteins such as Shc, PLC-γ and GAP, which play important roles in the signal 
transduction pathway. Expression of c-erbB2 appears to be an attractive candidate. C-
erbB2 overexpression plays a very important role as a prognostic marker by itself and in 
correlation with other markers. The determination of c-erbB2 (HER2/neu) status in breast 
cancers is important for the selection of suitable candidates for anti-HER2/neu therapy. 
Hence, accurate and reliable testing methods are essential in ensuring that patients are 
appropriately managed. There is currently no clear standardization of methods for c-
erbB2 (HER2/neu) testing. 
Hypothesis: 
The hypothesis that will be tested in this study is that c-erbB2 is a marker of poor 
prognosis in Singapore women with breast cancer.  
 
The main objectives of this study are to: 
(1) Evaluate the overexpression of c-erbB2 protein in breast cancer in an 
Asian population by immunohistochemistry. 
(2) Evaluate c-erbB2 gene amplification by fluorescent in situ hybridization 
(FISH analysis) and factors affecting the retrieval of fluorescent signals from FISH. 
(3) Correlation of c-erbB2 overexpression with clinico-pathologic parameters 
such as tumor size, histologic subtype, histologic grade, pathological stage, 
lymphovascular invasion, lymph node status, ER and PR status. 
(4) To assess nuclear morphometric features of c-erbB2 overexpressing breast 
cancers. 
(5) Investigate the association of c-erbB2 with other biological markers such 
as Ki-67, iNOS and c-myc. 
(6) Determine the role of c-erbB2 overexpression as a prognostic marker by 













































































2.1 Patients and breast tissues 
 
 Archival as well as more current breast carcinoma tissues operated between 1995 
and 2002 at the Singapore General Hospital were used for this study. Primary invasive 
breast cancers from 321 Singapore women formed the study group. Surgical procedures 
comprised mastectomy or wide excision with axillary clearance and diagnostic trucut 
biopsies. Patients’ demographic profile such as age, gender and ethnicity were obtained 
from the pathology reports. Of 321 women in the study, 271(84.4%) were ethnic Chinese, 
23(7.2%) Malays and 14(4.4%) Indians and 13(4%) of other races.  Their ages ranged 
from 28 to 86 years, with a mean of 54 years.  The histological diagnosis was made on 
hematoxylin and eosin (H & E) stained slides according to standard criteria defined by 
the World Health Organization (WHO) and modified by Elston and Ellis (1998). Tissues 
were fixed in 10% buffered formalin and embedded in paraffin. Disease free survival 
(DFS) and overall survival (OS) were available for 290 patients. Event of interest was 
death from breast cancer, and all other causes of death were disregarded in the analysis. 
 
2.2 Histopathological diagnosis 
 Formalin fixed, paraffin-embedded tissues were cut at 4µm thickness and stained 
by the H & E method. Histopathological diagnoses were made in accordance to 






2.3.1 Staining procedure for light microscopy 
2.3.1.1 Sectioning, dewaxing and rehydration  
 Four µm sections were cut from appropriately selected paraffin blocks containing 
lesional tissue using a rotary microtome (Leica RM 2135). These were mounted on 
Polysine, coated glass slides (Menzel - Glaser, Art no. 041400), heated on a hot plate at 
60˚C for 30 min and incubated for 1 hr at 55˚C. The sections were dewaxed in 3 changes 
of xylene, rehydrated through a series of graded alcohol (2 changes of absolute alcohol to 
wash away xylene, followed by 95% and then 70% alcohol, 5 min duration each for 
rehydration) and put under running tap water. 
2.3.1.2 Antigen retrieval 
 When antigen retrieval was required, sections were heated appropriately as in 
Table 7.  Duration and method of heating were modified according to the primary 
antibody used for the appropriate antigens, before allowing to cool down to room 
temperature in the buffer.   
2.3.1.3 Blocking of endogenous peroxidase 
 After rinsing with Tris Buffered saline (TBS, pH 7.6),  endogenous peroxidase 
activity was quenched by immersing the sections in 3% hydrogen peroxide (H2O2) in 
TBS/methanol for 10 min, followed by repeated washing in running tap water. 
2.3.1.4 Blockage of nonspecific binding sites 
 Nonspecific binding sites were blocked by 10% swine serum for 10 min. Sections 
were incubated in normal host serum of the secondary antibody (for example, if the 
primary antibody is for a mouse host, and the secondary antibody is horse anti-mouse 
IgG antibody, the blocking serum should be normal horse serum) at 1:20 dilution for 1hr 
at room temperature (RT). 
2.3.1.5 Specific binding of primary antibody 
 After blocking of nonspecific antibody binding sites with the normal serum, 
sections were incubated with relevant primary antibodies at various optimal dilutions in a 
humid chamber for 30 min at room temperature. The dilution of antibodies is shown in 
Table 7. 
2.3.1.6 Detection of the specific primary antibody binding sites 
 The primary antibody was rinsed off with Tris buffered saline (TBS) (5min x 3 
times) at pH 7.4 to remove the nonspecific binding of primary antibody. Then sections 
were incubated with relevant linking biotinylated antibody (Dako LSAB ChemMate kit, 
K5001) for 30 min at room temperature. This was then rinsed off with TBS and followed 
by incubation with peroxidase-conjugated streptavidin complex (Dako LSAB ChemMate 
kit, K5001) for 30 mins. Freshly prepared DAB (50mg DAB in 100ml TBS at present of 
33µl H2O2) solution (Dako LSAB ChemMate kit, K5001) was applied for 7 min after the 
tertiary layer was rinsed off with TBS. 
2.3.1.7 Counterstain, dehydration and mounting  
 The excessive DAB solution was removed by rinsing with running tap water. The 
slides were counterstained with hematoxylin for 2 min, washed in running tap water and 
differentiated in 1% acid alcohol (1 dip) and blued in running tap water. The sections 
were then dehydrated via a series of graded alcohols (70%, 95% and Absolute) cleared 
and mounted in depex with coverslip. 
 
2.3.1.8 Controls of immunohistochemistry 
  Each run of immunohistochemistry detection involved both negative and positive 
controls. Negative controls were obtained by omitting the primary antibody and positive 
controls were obtained by including a known positive. 
 




Clonality Host Species Dilution Antigen Retrieval 
Antibody 
Source 
C-erbB2 A0485 Polyclonal Rabbit 1:1000 
Microwave in 600ml of 
0.01M citrate buffer, pH 
6 at 800W for 25 min 
Dako 
C-myc CBL430 9E19 Mouse 1:30 
Pressure cook in 0.01M 
citrate buffer, pH6 for 2 
min at maximum 
pressure 
Cymbus Biotech 
ER 760-2596 6F11 Mouse Neat 
Pressure cook in 0.01M 
citrate buffer, pH6 for 2 
min at maximum 
pressure 
Ventana 
PR M3569 PgR636 Mouse 1:2500 
Pressure cook in 0.01M 
citrate buffer, pH6 for 2 
min at maximum 
pressure 
Dako 
Ki-67 M7240 MIB-1 Mouse 1:100 
Microwave in 600ml of 
DK6 buffer (Dako, 
S1699), at 800W for 
25min 
Dako 
iNOS AB1631 polyclonal Rabbit 1:50 
Pressure cook in 0.01M 
citrate buffer, pH6 for 2 






2.3.2 Quantification of immunohistochemical staining 
 The immunohistochemistry results were assessed by the author and confirmed by 
a pathologist (Dr. Tan Puay Hoon, SGH). For semi-quantitative assessment, sections 
were analyzed under a light microscope (Zeiss, Axioplan) using a 40x or higher 
objective. The entire slide was screened and areas of interest studied. Although several 
tumor sections also contained areas of in situ carcinoma, only the invasive component 
was assessed for immunopositivity.  
2.3.2.1 Assessment of c-erbB2 immunopositivity 
An arbitrary classification system recommended by Dako (HER2 monograph) 
was used to grade the degree of membrane staining. No staining or membrane staining 
observed in <10% of tumor cells was taken as a score of 0, a faint/barely perceptible 
membrane staining detected in >10% of tumor cells was taken as 1+, weak to moderate 
and strong complete membrane staining observed in > 10% of tumor cells were regarded 
as 2+ and 3+ respectively.  A score of 0 and 1+ was considered negative and 2+ and 3+ 
as positive (Table 8). One section from each case has been scored. Staining was 
considered ‘indeterminate’ when c-erbB2 immunostaining was also observed in adjacent 
stroma or inflammatory cells, or if benign epithelium also showed membranous reactivity 










Table 8 Scores for c-erbB2 overexpression using the DAKO Hercep protocol (DAKO 
HercepTest-Package insert, 1999). 
 
Score C-erbB2 overexpression assessment Staining pattern 
0 Negative No staining is observed or membrane 
staining is observed in <10% of tumor 
cells 
1+ Negative A faint/barely perceptible membrane 
staining is detected in >10% of tumor 
cells. The cells are only stained in part 
of their membrane 
2+ Weak positive A weak to moderate complete 
membrane staining is observed in >10% 
of tumor cells 
3+ Strong positive A strong complete membrane staining is 
observed in >10% of tumor cells 
 
 
2.3.2.2 Assessment of ER and PR immunostaining 
 Positive ER and PR staining was defined as when 10% or more of tumor cell 
nuclei were immunoreactive. 
2.3.2.3 Assessment of Ki-67 immunoreactivity 
 Immunoreactivity of Ki-67 was expressed as a percentage based on 
semiquantitative assessment of the proportion of immunopositive cells. The 
immunoreactivity of the Ki-67 antibody was distributed in 4 categories: negative 
proliferative index (no detected positive cells), low (≤ 5% positive cells), moderate (6-
10% positive cells) and high (>10% positive cells). 
2.3.2.4 Assessment of iNOS immunostaining 
 Positivity of iNOS was confirmed when more than 10% of tumor cells showed 
cytoplasmic staining.  
 
2.3.2.5 Assessment of c-myc immunostaining 
 Cases in which more than 10% of tumor cells showed cytoplasmic staining were 
considered positive, irrespective of the nuclear positivity. Some tumors included cells 
with nuclear positivity.  
  
2.4 Fluorescence in situ hybridization (FISH) analysis of c-erbB2 oncogene 
2.4.1 Breast cancer tissues 
A total of 98 cases comprising both archival and more recent ones, were subjected 
to FISH evaluation.  To study the retrievel of FISH signals from archival paraffin blocks of 
breast cancer, sections were cut from the blocks stored between the years 1995-2001. 
 
2.4.2. Fixation duration  
 Tumor tissues were divided into three groups based on duration of fixation in 10% 
buffered formalin. Two sets of tumor tissues from each case were allotted into three 
groups. They were fixed in 10%  buffered formaldehyde for 12 ± 2.5 hrs (range 9-18 hrs, 
median 12 hrs) and  27 ± 3.0 hrs (range 20–32 hrs, median 27 hrs) in the first group; 2 hrs 
and 17.5 ± 1.5 hrs (range 16-20 hrs, median 17.5 hrs) in the second group; and 28.5 ± 2 hrs 
(range 26-30 hrs, median 28.5 hrs) and 541 hrs ± 285 hrs (range 193-1010 hrs, median 541 
hrs) in the third group. All cases in the first group represented the usual range of fixation 
duration for breast surgical specimens routinely handled in the laboratory; while the 
second and third groups were used to test the effect of a shortened fixation duration (2 hrs) 
and an extended fixation duration (median 541 hrs) on FISH results, as compared with 
routinely fixed cases. 
2.4.3 Fixation protocols 
 The tumor tissues were divided into two groups: archived samples less than 12 
months’ duration and archived samples more than 12 months’ duration. Paraffin sections 
cut from the stored paraffin blocks were subjected to routine and modified FISH protocols 
(Table 9). 
Table 9 Different protocols of protein digestion and pretreatments used for groups 
 Modified Protocols 
Protocol I Protease 5mg/ml, for 1 hr; NaSCN at 80˚c for 30mins 
Protocol II Protease 1.5mg/ml, for 2hrs; NaSCN at 80˚c for 30mins 
Protocol III Protease 1.5mg/ml, for 2.5hrs; NaSCN at 80˚c for 30mins 
Protocol IV Protease 1.25mg/ml, for 1hr; NaSCN at 80˚c for 30mins 
Protocol V Protease 0.5mg/ml, for 40mins; NaSCN at 80˚c for 1hr 
Protocol VI Protease 0.5mg/ml, for 40mins; NaSCN at 80˚c for 30 mins 
 
2.4.4 Microwave oven fixation 
 In this arm, tumor tissue from 7 cases was divided into two groups. One group was 
fixed in 10% buffered formaldehyde hastened by microwave oven heating at 55˚C for 2.5 
minutes and the other group was fixed in 10% buffered formalin for durations ranging 
from 12 to 27 hrs before paraffin-embedding. 
2.4.5 Hybridization procedure 
2.4.5.1 Sectioning, dewaxing and rehydration 
 Three µm thick sections were cut for FISH analysis and mounted on glass slides 
coated with silane (3-aminopropyltriethoxysilane, Sigma). Briefly, slides were heated 
overnight (56oC). The sections were deparaffinized and pretreated to facilitate probe 
permeability using a Pretreatment Kit (Vysis, Downers Grove, IL) according to 
manufacturer’s instructions with minor modifications. This was followed by de-waxing in 
xylene for 10 min (3 changes), then rehydrated in absolute alcohol for 5 min (2 changes) 
and then air dried. 
2.4.5.2 Acid treatment and pretreatment with sodium thiocyanate 
 Air dried slides were treated with 0.2N HCl for 20 min at room temperature (RT). 
The slides were then immersed in deionised water for 1 min and then washed in buffer 
for 3 min. This was followed by incubation in 1M sodium thiocyanate in 2XSSC (0.5M 
NaCl, 0.015M sodium citrate) at 80oC for 30 min, followed by immersion in deionised 
water for 1 min, and  in wash buffer for 5 min (2 changes). 
2.4.5.3 Protein digestion 
 The slides were digested with protease (0.5 mg/ml) for 30 min at 37oC then, 
immersed in wash buffer for 5 min (2 changes) and then air dried. 
2.4.5.4 Detergent treatment and dehydration 
 Slides are soaked in detergent solution (0.5% Tween-20 in 2X SSC, pH 7) at 37˚C 
for 40 min then dehydrated via a series of graded alcohols (70%, 85%, 95%, 100%, and 
100%) for 2 min each. Then the slides are air dried and subjected to probe protocols. The 
pretreatment protocols were modified according to the categories and groups studied. 
2.4.5.5 Probe protocol 
 In situ hybridization was performed using the PathVysion HER2 DNA Probe Kit 
(Vysis, Downers Grove, IL) (Selvarajan et al. 2002). 3µl of the hybridization solution 
containing the probe (LSI/CEP17) was applied to the treated slides and the areas were 
covered with 12mm diameter coverslips and sealed with rubber solution. The slides were 
then placed in a slide thermocycler (Hybaid Omnislide) programmed to co-denature the 
probe and target the DNA. Slides were incubated with hybridization solution at 75oC for 
5 min, and subsequently at 38oC for 16 hr overnight. 
2.4.5.6 Post-hybrid wash and mounting 
 After overnight incubation the slides were taken out of the thermocycler and the 
cover slips were peeled off the seal. The slides were washed 2 times in 0.1% NP-40 in 
0.5X SSC at 70˚C for 3 min, then washed in wash buffer at RT for 2 min, counterstained 
in DAPI (0.1 g/ml in 2 x SSC), then mounted with antifade (Vectashield) and bordered 
with nail polish. 
 
2.4.6 Quantification of FISH signals 
Once the slides were hybridized and post-hybridization washes done, they were 
mounted with antifade (Vectashield) and viewed under an epifluorescence microscope 
(Olympus), with the images captured (CytoVision). Sixty nuclei were counted. Signal 
enumeration was performed with the following conditions:  overlapping nuclei were 
excluded and split signals were counted as 1 chromosome component (Hoang et al., 
2000). Stromal and inflammatory cells were excluded from analysis on the basis of the 
morphologic features of their nuclei. The criteria for gene amplification were (a) >4 
signals per cell and (b) the HER2/neu to CEP 17 ratio > 2 (Ellis et al., 2000; Ridolfi et al., 
2000).   
 
 
2.5 Nuclear morphometry 
2.5.1 Breast cancer tissues 
 Ninety-six cases were randomly selected for assessing nuclear morphometry. C-
erbB2 immunostained breast cancer tissues were used for analysis. Only the invasive 
breast carcinoma component was included for the image cytometry and not the DCIS 
component. 
2.5.2 Image cytometry 
 Nuclear image analysis was performed on a light microscope (Axioplan, Zeiss), 
equipped with a Carl Zeiss camera linked to a computer, using the Imagepro software. 
Cell nuclei from digitized images were outlined using a mouse. For each case, a minimum 
of 100 nuclei of cancer cells was randomly selected for morphometric analysis. 
Morphometric parameters measured were nuclear area, nuclear perimeter, and roundness. 
For comparison of nuclear size and shape between the two populations of stained and 
unstained cells in each c-erbB2 positive case, 50 cells from each group were analyzed. 
 
2.6 Statistical analysis 
 The results were analysed using the statistical software SPSS for Windows, 
version 11 and the GraphPad Prism statistical Package.  Association of c-erbB2 
membrane staining status with clinico-pathologic parameters like age group, tumor size, 
histologic subtype, histologic grade stage lymphovascular invasion, nodal status, ER and 
PR were analyzed using the Chi-square χ2 test. The Student’s paired t-test was performed 
to compare means and Chi-square χ2 test for comparing proportions in FISH analysis. For 
comparison of c-erB2 expression and nuclear morphometry, one-way ANOVA was 
performed to compare means. Association of c-erbB2 membrane staining status with 
biologic markers like Ki-67, iNOS and c-myc were analyzed using the Chi-square χ2 test. 
Association of biological markers like Ki-67 and iNOS with clinico-pathologic markers 
like ethnicity, tumor size, histologic subtype, histologic grade, lymphovascular invasion, 
nodal status, ER, PR and p53 were analyzed using the Chi-square χ2 test. Overall survival 
curves were calculated using the method of Kaplan and Meier and differences between 




















































Correlation of clinicopathological features with c-erbB2 status 
3.1 Histopathology 
 Paraffin-embedded, archival breast carcinoma tissues from 321 women operated 
between 1998 and 2002 at the Singapore General Hospital were used for this study. 
Tumor size measured between 0.2 to12 cm with a mean of 3 cm and a median of 2.5 cm.  
 Tumors were histologically subtyped and graded according to recommended 
guidelines (Sloane et al., 1995).  Histopathological subtyping revealed 266 infiltrative 
ductal carcinomas, with the rest categorized as invasive mucinous, lobular, mixed ductal-
lobular, papillary and tubular. Histologic grading took into account three criteria: amount 
of tubule formation, nuclear pleomorphism and mitotic rate. Forty-six (14.3%) cases were 
classified as grade 1 (Fig 4), 132 (41.1%) cases as grade 2(Fig 5) and 127(39.6%) cases 
as grade 3(Fig 6).  In 16 (5%) cases, histological grading could not be accurately 
determined because of small tumor quantum. When staged by the AJCC-TNM system, 68 
tumors (23%), 192 tumors (65.1%), 28 tumors (9.5%) and 7 tumors (2.4%) were grouped 
as stage 1, 2, 3 and 4 respectively.  In 26 cases, pathologic staging could not be achieved 
because of unavailability of axillary lymph nodal status. Patient details and 
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Fig. 4 A histologic grade 1 tumor showing predominant  tubules with mild to moderately 







Fig. 5 A histological grade 2 tumor showing the presence of trabeculae with scanty 
tubules, moderately pleomorphic nuclei and few mitoses. (H & E stain, Original 







Fig. 6 A histological grade 3 tumor displaying no tubules and nuclei which are irregular 
in size and shape and mitoses are obvious. (H & E stain, Original magnification x 310). 
 
 
3.2 Hormone receptor status 
As evaluated by immunohistochemistry in histopathologically diagnosed cases of 
invasive ductal breast carcinoma, 66.4% of the tumors were ER positive and 46.9% were 
PR positive (Table 11). Examples of ER and PR positive immunostaining are shown in 
Fig 7 and Fig 8 respectively. 
Table 11 Hormone receptor status in invasive breast carcinoma 
 PR+ PR- Total 
ER+ 137 74 211 
ER- 12 95 107 







Fig. 7 Invasive ductal breast carcinoma showing strong nuclear positivity for ER in 







Fig. 8 Invasive ductal breast carcinoma showing strong positive reactivity of the nuclei 






3.3 C-erbB2 detection 
3.3.1 C-erbB2 immunostaining at protein level-Immunohistochemistry (IHC) 
C-erbB2 immunopositivity was detected in 110 (34.3%) cases, with 208 (64.8%) 
cases defined as negative. The distribution of the different immunostaining intensities of 
c-erbB2 in this study is shown in Fig 9. In 3 cases (1%), the staining was indeterminate as 



















The different patterns of immunostaining are shown in Figures 10-13. A 
component of ductal carcinoma in situ was found in 30% to 40% of cases (Fig 14). C-
erbB2 expression was also present in the in situ cancer cells, with similar staining 






Fig. 10 C-erbB2 immunostaining of invasive ductal breast cancer tissues. Negative 



















Fig. 11 C-erbB2 immunostaining of invasive ductal breast carcinoma. 1+ staining 









Fig. 12 C-erbB2 immunostaining of invasive ductal breast carcinoma. 2+ positive 







Fig. 13 C-erbB2 immunostaining of invasive ductal breast carcinoma. 3+ positive 






Fig. 14 Ductal Carcinoma in situ component (shown in arrows) of invasive ductal breast 




3.3.2 C-erbB2 amplification at gene level-Fluorescence in situ hybridization (FISH) 
A total of 98 cases were subjected to FISH for detection of c-erbB2 gene 
amplification. All the cases were grouped into three arms based on specific criteria as 
elaborated in the methods. 
3.3.2.1 C-erbB2 gene amplification and fixation duration  
 The purpose of this arm was to ascertain if variations in fixation duration in 
buffered formalin had any impact on the reliability of HER2/neu amplification results 
obtained via FISH. Out of 35 cases, two sets of tumor tissues from each case were 
allotted into three groups. There was no significant difference in detection of FISH 
signals with respect to the 12 hour or 27 hour fixation protocols in the first group (P = 
0.476, Table 12, Fig 15 and 16.) indicating that the range of fixation times used routinely 
in the surgical pathology laboratory did not affect FISH results. Out of 4 amplified cases 
in this group, 2 cases revealed very high levels of gene amplification as shown by the 
HER2/neu-CEP17 ratio of 13.24, 10.6 and 14.65, 9.5 for the 12 hr and 27 hr fixation 
protocols, respectively. In the second group, there was also no significant difference in 
FISH results between the 2 hr or 17.5 hr fixation protocols (P = 0.151, Table 13, Fig 17 
and 18).   In the third group, signals were detected in all 6 cases in the 28.5 hr fixation 
protocol but only 2 cases showed signals in the extended duration fixation protocol (cases 






Table 12 C-erbB2 (HER2/neu) FISH and immunostaining of formalin fixed breast cancer 










1 NA 1.054 1.29 POS 2+ 
2 NA 1.008 1.008 NEG 0 
3 NA 1.134 1.102 POS 2+ 
4 NA 1.155 1.095 NEG 0 
6 A 2.366 2.445 POS 3+ 
7 NA 1.016 1.032 POS 2+ 
8 NA 1.00 1.057 POS 2+ 
9 NA 1.008 1.039 NEG 0 
10 NA 1.015 1.064 POS 2+ 
11 NA 1.2 1.2 NEG 0 
12 A 13.238 14.651 POS 3+ 
13 NA 1.058 1.074 NEG 1+ 
14 NA 1 1.043 NEG 0 
15 A 10.6 9.5 POS 3+ 
16 NA 1.049 1.107 POS 2+ 
17 A 2.451 2.58 POS 3+ 
18 NA 1.04 1.056 NEG 1+ 
19 NA 1.069 1.102 NEG 0 
20 NA 1.339 1.627 NEG 0 
21 NA 1.378 1.482 NEG 0 
A- amplified; NA- not amplified; POS-positive; NEG-






Fig. 15 FISH post 12 hr fixation. The green signal shows presence of centromere 17 
copies while the red signal represents multiple copies of the c-erbB2 (HER2/neu) gene. 







Fig. 16 FISH post 27 hr fixation. The green signal shows presence of centromere 17 
copies while the red signal represents multiple copies of the c-erbB2 (HER2/neu) gene. 
Original magnification x 100 objective. 
 
 
Table 13 C-erbB2 (HER2/neu) FISH and immunostaining of formalin fixed breast cancer 










1 NA 1.146 1.133 NEG 0 
2 A 2.031 2.019 POS 2+ 
3 NA 1.065 1.094 NEG 0 
4 NA 1.057 1.073 NEG 0 
5 NA 1.041 1.041 NEG 0 
6 A 2.295 2.16 POS 2+ 
7 NA 1.124 1.08 NEG 0 
8 A 5.206 5.058 POS 2+ 
A- amplified; NA- not amplified; POS-positive; 
NEG-negative.RATIO-ratio of HER2/neu to CEP17 
signals. * 0 – No staining is observed in tumor cells; 
2+ - A weak to moderate complete membrane 




















Fig. 17 FISH post 2 hr fixation. The green signal shows presence of centromere 17 copies 
while the red signal represents multiple copies of the c-erbB2 (HER2/neu) gene. Original 





Fig. 18 FISH post 17.5 hr fixation. The green signal shows presence of centromere 17 
copies while the red signal represents multiple copies of the c-erbB2 (HER2/neu) gene. 
Original magnification x 100 objective. 
 
Table 14 C-erbB2 (HER2/neu) FISH and immunostaining of formalin fixed breast cancer 










1 A 6.06 4.27 POS 2+ 
2 NA 1.025 1.025 NEG 0 
3 NA 1.176 *** NEG 0 
4 NA 1.363 *** NEG 0 
5 NA 1.192 *** NEG 0 
6 A 4.085 *** POS 2+ 
A- amplified; NA- not amplified; ***-no signals; 
POS-positive; NEG-negative. RATIO-ratio of 
HER2/neu to CEP17 signals. * 0 – No staining is 
observed in tumor cells; 2+ - A weak to moderate 


























Fig. 19 FISH post 28.5 hr fixation. The green signal shows presence of centromere 17 
copies while the red signal represents multiple copies of the c-erbB2 (HER2/neu) gene. 





Fig. 20 FISH post extended duration of fixation. The green signal shows presence of 
centromere 17 copies while the red signal represents multiple copies of the c-erbB2 
(HER2/neu) gene. Original magnification x 100 objective. 
 
3.3.2.2 C-erbB2 gene amplification and fixation protocols  
The purpose of this arm was to evaluate the effect of different protocols in the 
retrieval of fluorescent signals from FISH analysis of the c-erbB2 gene in archival 
paraffin-embedded breast cancer tissue blocks. 63 archival paraffin-embedded breast 
cancer tissue blocks were grouped into two: archived samples less than 12 months’ 
duration and archived samples more than 12 months’ duration. All the archived 
specimens less than 12 months’ duration (mean 5.8 months; median 3.5 months) 
exhibited hybridization signals with the routine protocol (Table 15; Fig 21). In the group 
where the specimens were archived for more than 12 months’ duration (mean 47 months, 
median 49.5 months), we obtained signals in 10 specimens after manipulating the 
treatment procedure (Table 16; Fig 22). No fluorescent signals were detected with the rest 
















Table 15 C-erbB2 (HER2/neu) FISH of formalin fixed paraffin-embedded archival breast 





IN MONTHS PROTOCOL FISH RATIO 
1 11.5 Routine A 2.58 
2 5.0 Routine A 4.69 
3 7.5 Routine A 8.8 
4 10.2 Routine A 7.88 
5 10.2 Routine NA 1.10 
6 8.4 Routine A 8.50 
7 3.4 Routine NA 1.16 
8 2.6 Routine NA 1.24 
9 2.9 Routine NA 1.08 
10 3.5 Routine NA 1.10 
11 3.5 Routine A 3.16 
12 3.5 Routine A 3.84 
13 3.2 Routine A 3.19 
aA, amplified; NA, not amplified; RATIO, ratio of 





Fig. 21 FISH of archival paraffin-embedded breast cancer tissues stored less than 
12months’. Green signals show presence of centromere 17 copies and red signals 
represent multiple copies of c-erbB2 (HER2/neu) gene. Original magnification x 100 
objective. 
 
Table 16 C-erbB2 (HER2/neu) FISH of formalin fixed paraffin-embedded archival breast 




IN MONTHS PROTOCOL FISH RATIO 
1 83.7 I NA 1.26 
2 64.9 V A 5.3 
3 56.9 VI NA 1.7 
4 57.9 III A 5.9 
5 54.8 II A 4.2 
6 24.5 VI A 9.0 
7 12.6 IV A 3.37 
8 53.7 VI A 5.8 
9 37.5 I A 10.5 
10 30.9 VI A 8.8 
11 - 30 23.6 - 87.2 Routine and  I *** - 
31 - 40 38.1 - 56.6 Routine and VI *** - 
41 - 50 27.8 - 45.9 Routine and V *** - 
aA, amplified; NA, not amplified; ***, no signals; 






Fig. 22 FISH of archival paraffin-embedded breast cancer tissues stored more than 12 
months’duration (B). Green signals show presence of centromere 17 copies and red 
signals represent multiple copies of c-erbB2 (HER2/neu) gene. Original magnification x 
100 objective. 
 
3.3.2.3 C-erbB2 gene amplification and microwave oven fixation  
In this arm, there was no significant difference in the detection of FISH signals 
with respect to the microwave oven or routine fixation protocols in the 7 breast cancer 
cases (P = 0.637, Table 17). 
 
Table 17 C-erbB2 (HER2/neu) FISH of formalin fixed breast cancer tissues (microwave 











1 NA 1.15 1.16 
2 NA 1.20 1.24 
3 NA 1.11 1.08 
4 NA 1.10 1.11 
5 A 3.28 3.16 
6 A 3.47 3.84 
7 A 3.26 3.19 
aA, amplified; NA, not amplified; Pos, 
positive; Neg, negative; RATIO, ratio 










3.3.3 Correlation of c-erbB2 protein overexpression and gene amplification 
 35 cases in the first arm were used to compare the gene amplification and protein 
overexpression of c-erbB2. In cases where FISH signals were detected, there was a 
positive correlation between c-erbB2 gene amplification by FISH and protein expression 
by immunohistochemistry (P = 0.0002) in all the groups. All tissues with 3+ IHC staining 
disclosed c-erbB2 amplification, (Fig 23) whereas those with negative immunostaining (0 
and 1+ IHC staining) showed no c-erbB2 gene amplification (Table 12, 13, 14). There 
was no gene amplification detected in the 6 immunopositive cases with 2+ IHC staining 
in group 1 of the first arm (Table 12), while in the other groups (Table 13, 14), it showed 






Fig. 23 FISH post (A) 12 and (B) 27 hr fixation. The green signal shows presence of 
centromere 17 copies while the red signal represents multiple copies of the c-erbB2 
(HER2/neu) gene. (C)Immunostaining for c-erbB2 (HER2/neu) (3+), showing a 
complete, intense membranous pattern of positivity. Original magnification X 400. 
 
 
3.4 Association of c-erbB2 overexpression with nuclear morphometry  
For nuclear morphometry, c-erbB2 positive and negative tumors differed 
significantly only in nuclear roundness, with malignant cells in c-erbB2 positive cases 
being less round (P = 0.0322, Table 18) (Fig. 24 & 25). There was no statistically 
significant difference in nuclear morphometry findings between immunopositive versus 
immunonegative malignant cells in the c-erbB2 positive cancers. When analyzing the 
association of nuclear morphometric data in relation to histopathologic parameters in the 
group of c-erbB2 positive breast cancers, there was a significant difference in (a) nuclear 
area and perimeter between histological grade 3 and histologic grade 1 and 2 (P = 0.001 
and P = 0.03 respectively) and (b) nuclear perimeter between tumor size ≤  20 mm and 
tumor size > 20 mm (P = 0.046) (Table 19).  
 
 













119.2 ± 5.6 116.2 ± 5.1 0.7039 
Perimeter* 




1.23 ± 0.009 1.2 ± 0.009 0.0322 










Fig. 24 Nuclei of c-erbB2 positive invasive ductal carcinoma digitally outlined using a 
computer mouse. Note that most of the nuclei are not so round or oval as in c-erbB2 







Fig. 25 Nuclei of c-erbB2 negative invasive ductal carcinoma digitally outlined using a 
computer mouse. Note that most of the nuclei are round or oval in configuration. (IHC 
staining; Original magnification x 400). 
 
 
Table 19 Nuclear morphology of malignant cells with respect to clinico-pathologic 















Grade 1 or 2 
 
107.56* ± 35.68 39.62* ± 7.87 1.2 ± 0.17 1.44 
Histologic 
grade Grade 3 
 
142.36*± 47.55 44.6* ± 9.62 1.2 ± 0.18 1.47 
≤  20mm 
 
110.76 ± 36.23 39.31* ± 7.29 1.2 ± 0.16 1.47 
Tumor size >  20mm 
 
133.99 ± 45.43 44.05* ± 9.7 1.19 ± 0.17 1.42 
Yes 
 
122.22 ± 44.54 41.97 ± 9.13 1.28 ± 0.2 1.45 
LV Invasion No 
 
115.33 ± 37.2 40.88 ± 8.16 1.2 ± 0.16 1.45 
Neg 
 
119.06 ± 35.7 41.12 ± 8.06 1.2 ± 0.16 1.47 
Node status Pos 
 
126.62 ± 45.48 42.93 ± 9.82 1.19 ± 0.18 1.41 
Neg 
 
125.8 ± 47.26 42.36 ± 9.39 1.2 ± 0.17 1.47 
ER Pos 
 
113.97 ± 34.49 40.57 ± 8.04 1.2 ± 0.18 1.43 
Neg 
 
117.32 ± 40.83 40.89 ± 8.43 1.2 ± 0.17 1.47 
PR Pos 
 
118.13 ± 64.04 41.58 ± 8.49 1.21 ± 0.18 1.43 
 




















3.5 Association of c-erbB2 overexpression with established clinicopathological and 
biological markers 
 
3.5.1 Association of c-erbB2 overexpression and hormone receptor status  
A significant negative association between c-erbB2 expression and ER and PR 
status was noted (P = 0.0001; Table 20 and 21). 
              
 
 






C-erbB2 - 53 152 205 
C-erbB2 + 53 57 110 
Total 106 209 315 
0.0001 
 










C-erbB2 - 94 111 205 
C-erbB2 + 74 36 110 






3.5.2 Relationship between c-erbB2 overexpression and clinicalpathological 
parameters in invasive breast carcinoma 
 
Immunohistochemical expression of c-erbB2 protein and other clinico-
pathological parameters in a series of Singapore women with invasive breast carcinoma 
are documented in Table 22. The findings were correlated with pathologic parameters 
such as age at diagnosis, tumor size, histologic subtype, histologic grade, pathological 
stage, lymphovascular invasion and lymph node status (Table 22). 
3.5.2.1 Association of c-erbB2 overexpression and histological grade 
 There was a significantly higher c-erbB2 overexpression in histological grade 3 
tumors than in histological grade 1 and 2 tumors.  
3.5.2.2 C-erbB2 overexpression and other clinicopathological factors  
 There was no statistically significant difference in c-erbB2 overexpression with 
regard to patient age, histologic subtype, lymphovascular invasion, pathologic stage, 











Table 22 Correlation between c-erbB2 overexpression and clinicopathological parameters 
 * Missing values range from 2 to 26 
 
 






No. of Patients 
Positive P-value 
 
Total                                                     321* 
             
Age group 
        ≤ 50 
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      Grade 1  
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     Negative 












3.5.3 C-erbB2 overexpression with Ki-67(cell proliferation index) 
 The percentage of Ki-67 immunostaining (KI) detected in the 72 cases ranged 
from nil to 80%. An example of Ki-67 positive stained breast cancer section along with 
negative control is shown in Fig 26 and 27.  














C-erbB2 - 8 15 4 27 54 
C-erbB2 + 3 2 2 10 17 













Fig. 26 Positive Ki67 immunostaining showed nuclear positivity of the proliferating 
cancer cells of invasive breast carcinoma. (Hematoxylin counterstain; Original 







Fig. 27 Negative control (by omission of primary antibody) showed no Ki67 
immunostaining of the cancer cells of invasive breast carcinoma. (Hematoxylin 
counterstain; Original magnification x 310). 
 
 
3.5.4 C-erbB2 overexpression with iNOS 
 Cells with more than 10% cytoplasmic staining for iNOS were considered 
positive. Out of 72 cases, 34 (47.2%) were considered positive and the rest were negative. 
An example of a strong iNOS positive section is shown in Fig 28, along with a negative 
control (Fig 29). 
 There was no significant correlation between c-erbB2 overexpression and iNOS 











C-erbB2 - 31 23 54 
C-erbB2 + 7 10 17 
Total 38 33 71 
0.242 
One case has no c-erbB2 value so is not 












Fig. 28 iNOS immunostaining showed strong cytoplasmic positivity of the cancer cells of 







Fig. 29 Negative control showed no iNOS immunostaining of the cancer cells of invasive 





3.5.5 C-erbB2 overexpression with c-myc 
 The expression of c-myc was studied in 34 cases of invasive breast carcinoma. 
Cells with more than 10% cytoplasmic staining were considered positive. All carcinomas 
showed positive cytoplasmic staining except two cases. An example of an 
immunopositive section is shown, along with negative control in the Fig 30 and 31. 
 C-myc gene expression did not show any association with c-erbB2 













C-erbB2 - 2 17 19 
C-erbB2 + - 15 15 














Fig. 30 Positive c-myc  immunostaining showed nuclear as well as cytoplasmic positivity 
of the cancer cells of invasive breast carcinoma. (Hematoxylin counterstain; Original 







Fig. 31 Negative control showed no c-myc immunostaining of the cancer cells of invasive 





3.5.6 Association of biological markers with clinicopathological parameters in invasive 
breast carcinoma 
Clinicopathological data in 72 cases which were subjected to 
immunohistohemical evaluation of Ki-67, iNOS and c-myc are shown in Table 26. Cases 
with missing values are eliminated from the statistical analysis. Univariate analysis of the 
association between clinicopathological parameters and these markers is displayed in 
Table 27. 
3.5.6.1 Ki-67 
 Ki-67 showed a positive association with histologic grade and histologic 
subtypes. Remaining parameters did not have any correlation with cell proliferation. 
Histologic grade 3 tumors and invasive ductal carcinoma subtypes had higher 
proliferation indices than lower grade tumors and other histologic subtypes. 
3.5.6.2 iNOS 
 iNOS expression showed a positive correlation with lymph node status. 84.5% 
had axillary lymph node metastasis in those cases which showed iNOS expression 
(22/26). None of the other parameters had any association with iNOS expression. 
3.5.6.3 C-myc 
 C-myc protein expression did not show any association with any of the 










Table 26 Distribution of clinicopathological parameters and biological markers 
 
Parameter Classification No. of patients (%) 
Total Patients  72* 
Age Median 54 
 Mean 55.35 
 Range 36-85 
Ethnicity Chinese 60 (3.3%) 
 Malay 8 (11.1%) 
 Indian & 
Others 
4 (5.6%) 
Tumor size ≤25mm 24 (35.8%) 
 >25mm 43 (64.2%) 
Histologic subtype Ductal 62 (86.1%) 
 Others 10 (13.9%) 
Histological grade I 10 (14.3%) 
 II 34 (48.6%) 
 III 26 (37.1%) 
Lymphovascular invasion Present 40 (57.1%) 
 Not present 30 (42.9%) 
Lymph node status Positive 19 (33.3%) 
 Negative 38 (66.7%) 
Stage I 7 (13.3%) 
 II 35 (66%) 
 III 6 (11.3%) 
 IV 5 (9.4%) 
C-erbB2 Positive 17 (23.9%) 
 Negative 54 (76.1%) 
Ki-67 0- 5% 28 (38.9%) 
 5-10% 6 (8.3%) 
 > 10% 38 (52.8%) 
iNOS Positive 34(47.2%) 
 Negative 38 (52.8%) 
*-Not all 72 cases are reflected in all parameters. Cases 













 0.5 0.343 
Tumor size 


















 0.714 0.797 
ER 
 0.13 0.928 
PR 
 0.214 0.42 
p53 
 0.119 0.424 
*-statistically significant values (P < 0.05). 
Invasive ductal subtype and histological grade 








3.6 Follow up and survival analysis 
3.6.1 Kaplan-Meier survival analysis 
 In the 290 women with mean and median follow-up of 18 months and 17 months 
respectively, 15 deaths from breast carcinoma (5.2%) were documented. The OS for c-
erbB2 positive and c-erbB2 negative patients is illustrated in Fig 32, with mean survival 
of 43 months for c-erbB2 positive patients and 45 months for c-erbB2 negative ones. This 
difference in OS is statistically significant (P = 0.0166), indicating an adverse prognosis 
for the c-erbB2 positive cases.  A similar trend was noted for DFS with mean survival of 
10 months before detection of recurrence for c-erbB2 positive patients and 11 months for 
c-erbB2 negative ones, although the difference did not reach statistical significance (P = 
0.7013) (figure not shown). Different combinations of tumor characteristics for possible 
additive prognostic capacities were also investigated. In the node positive group, 
statistically significant difference was observed in OS for c-erbB2 negative patients 
compared to c-erbB2 positive patients, with mean survival period of 40 months and 48 
months respectively (P=0.0047; Fig 33). Patients with histologic grade 1 and 2 tumors 
experienced improved OS for c-erbB2 negative tumors compared to c-erbB2 positive 
ones, with mean survival of 46 months and 42 months respectively (P = 0.0367; Fig 34). 
When c-erbB2 and estrogen receptor (ER) status were combined, c-erbB2 status had a 
negative effect on the prognosis  of the estrogen receptor (ER) positive group with OS 
curves of c-erbB2 positive and negative patients within the ER positive subset differing 
significantly, with a mean survival period of 40 months and 47 months respectively (P = 
0.0092; Fig 35). C-erbB2 expression did not have any effect on OS in the estrogen 
receptor negative group of cases and in women aged ≤ 50 years. In those > 50 years of 
age, the mean survival was 41 months for c-erbB2 positive patients and 47 months for c-








Fig. 32 Kaplan-Meier curves for overall survival (OS) with regard to c-erbB2 




















































Fig. 33 Kaplan-Meier curves for overall survival (OS) stratified by c-erbB2 status, in 






















































Fig. 34 Kaplan-Meier curves for overall survival (OS) stratified by c-erbB2 status, in 













































P = .0367 
  
  





Fig. 35 Kaplan-Meier curves for overall survival (OS) stratified by c-erbB2 status, in 























































Fig. 36  Kaplan-Meier curves for overall survival (OS) stratified by c-erbB2 status, in 







































P = .0096 
  
  
Survival time in months
3.6.2 Multivariate Cox regression analysis 
Multivariate analysis by Cox regression model showed c-erbB2 overexpression to 
be an independent predictor of overall survival (P = 0.029; Table 28) when histologic 
grade, nodal and ER status were considered. However, when tumor size and pathologic 
















Histologic Grade 0.831 

























































4.1 C-erbB2 (HER2/neu) status in invasive breast carcinoma 
4.1.1 Brief overview of c-erbB2 assessment 
  A wide range of assay methods have been used to detect Her2/neu or c-erbB2 
status in breast cancer. Each technique has its own advantages and disadvantages, some 
of which are summarized in Table 29.  
Table 29 Comparison of methods used to detect c-erbB2 status (modified from Perez et 
al., 2002; Schnitt, 2001; Dowsett et al., 2000; Molina et al., 1996) 
Methods Advantages Disadvantages 
IHC 
Detects protein overexpression. 
 
Relatively simple method that can be 
performed on sections cut from paraffin 
embedded or frozen tissues. 
 
Procedure time is very short and can be 
accomplished in any laboratory. 
 
No expert training required. 
 
Automation is applicable. 
 
FDA approved for therapy. 
 
Cost effective. 
Not a standardized technique. 
 
Sensitivity and specificity may vary for different 
antibodies.  
 
Controls need to be used for every run. 
 
No standardized scoring system. 
FISH 
Detects gene amplification. 
 





Quantitative assessment.  
 
Longer procedure time. 
 
Needs expert training for the procedures. 
 
Special instruments and reagents needed to interpret 
and proceed. 
 
Difficult to accomplish in all laboratories. 
 




Detects gene amplification. 
 
Good sensitivity and specificity. 
 
Expert training needed. 
 
Not an easy procedure. 
 
No FDA approval. 
 
No automation  
ELISA 
(serum) 
Detects protein overexpression (shed in 
serum). 
 
Highly sensitive and specific. 
 
Standardized technique.  
Cannot perform on slides. 
 




4.1.2 C-erbB2 protein overexpression by Immunohistochemistry (IHC) 
Immunohistochemistry is one of the most widely used tools for research and 
diagnosis. The practice of immunohistchemistry originated with Albert H. Coons and his 
colleagues in the early 1940’s (Polak and Van Noorden, 1997). One of the main 
diagnostic uses of IHC is to determine the nature of tumors. IHC has been specifically 
adapted and the most practical method to perform in the routine practice of pathology for 
detection of c-erbB2 protein overexpression using specific antibodies (Schnitt, 2001; 
Slamon et al., 1989; van de Vijver et al., 1988).  
IHC has been used in the past to identify overexpression of c-erbB2 protein on the 
cell membrane of breast cancer cells in fixed tissues. C-erbB2 protein detection in 
archival paraffin-embedded tissues is highly variable or even compromised due to certain 
factors. Factors which have to be considered are time and nature of tissue fixation; 
method of tissue processing; temperature of paraffin embedding; duration of storage 
(especially unstained slides); type of antibody used; and the staining procedure used 
(Dowsett et al., 2000). Although different methods of antigen retrieval are used, it should 
be optimized because high antigen retrieval may result in high rates of positivity and even 
benign cells are also highlighted, whereas inadequate antigen retrieval may yield false 
negative results (Lian and Tan, 2002).  Standardization of the procedures may be 
preferable to obtain reliable results. Many antibodies for example CB-11 (monoclonal 
antibody, Ventana), A0485 (polyclonal antibody, DAKO), Mab-1/Pab 1 (cocktail 
antibody) and HercepTest are used by many laboratories world wide.  Each antibody has 
different levels of sensitivity and specificity.  The HercepTest has high sensitivity and 
specificity, and has been approved by FDA for therapeutic applications. There is still 
debate on the reliability of IHC. The quality of IHC results can be improved by following 
a few steps such as: (1) standardizing tissue fixation and processing; (2) use of 
appropriate positive and negative controls; and (3) participation is external quality 
assurance programmes. 
 The role of c-erbB2 oncoprotein overexpression in invasive breast cancer has 
been widely investigated. C-erbB2 overexpression occurs in about a third of breast 
tumors and is linked to an adverse prognosis (Fitzgibbons et al., 2000). There is still 
controversy in the determination of immunopositivity of c-erbB2 status in invasive breast 
carcinoma. One researcher has considered membrane staining of any intensity in any 
malignant cell as indicating protein overexpression (Sjogren et al., 1998); yet another  has 
defined c-erbB2 positivity as only when “tumor cells showed intense circumferential cell 
membrane staining easily identified with a 10X objective” (Jacobs et al., 2000). Ellis and 
co-workers have recommended that if > 10% of breast tumor cells reveal moderate or 
strong complete membrane reactivity, c-erbB2 expression is considered as positive on 
immunohistochemistry using the HercepTest scoring method (Ellis et al., 2000). In this 
present study, we have considered moderate (2+) or strong (3+) membrane staining 
intensity in 10% or more of invasive carcinoma cells as positive. 
 Amplification or overexpression of c-erbB2 gene or protein has been reported by 
several studies to occur in 10-40% of primary breast carcinomas (Cho et al., 2003; 
Konigshoff et al., 2003; Hoff et al., 2002; Tsai et al., 2001; Hoang et al., 2000; Ross and 
Fletcher, 1999; Ross et al., 1998; Odagiri et al., 1994; Slamon et al., 1987;). The rate of c-
erbB2 immunoexpression in our study was 34.3%, which is within the range reported for 
breast cancers in the literature. Also in this present study, invasive ductal carcinoma 
exhibited higher c-erbB2 immunopositivity (36.1%) compared to other types like invasive 
lobular, invasive tubular, and others (25.5%). This is also in accord with that reported by 
Smith et al (1994). 
 
4.1.3 C-erbB2 gene amplification by Fluorescence in situ hybridization (FISH) 
  Fluorescence in situ hybridization is one of the most convenient assays currently 
used to assess c-erbB2 gene amplification. There are many factors which may affect the 
detection of fluorescent signals by FISH analysis. Technical limitations include the type 
of fixative used, artifacts caused by sectioning of tissue blocks, thickness of sections, 
storage of cut sections and probe penetration (Ellis et al., 2000; Gozetti et al., 2000; 
Thomson et al., 1993).  
 In our surgical pathology laboratory, specimens are generally fixed in 10% 
buffered formalin for a duration that varies from approximately 8 to 32 hours due to 
inherent vagaries of surgical schedules. It would appear from our study that a fixation 
period ranging from 2 hrs to 1 week would not affect FISH results.  Beyond one week 
however, no signals could be detected, with the exception of the highly amplified case 1 
in group 3 (refer to “Results” chapter).  Formalin fixation increases the complexity of 
cellular structure and chromatin condensation making it difficult for the probe to 
penetrate and interact with the target DNA (Thompson et al., 1994). It has been suggested 
that generally, the longer the primary fixation, the permeabilization step of pretreatment 
and enzyme digestion needs to be more aggressive (Pauletti and Slamon, 1999). 
However, we obtained similar results for the different fixation protocols in all 3 groups in 
this study even though we did not vary the permeabilization step, with the exception of 4 
cases in the extended fixation protocol where no signals were obtained.  Our finding is at 
variance with that of Goelz et al (1985) who reported previously that DNA isolated from 
formaldehyde fixed and embedded tissues was not affected by the length of time in 
fixation.   
FISH is a cytogenetic technique widely used to evaluate gene amplification and 
other genetic aberrations in fresh tumor tissues.  However, if FISH analyses could be 
easily applied to archival paraffin-embedded tumor tissues from patients with known 
clinical outcome, valuable information regarding the diagnostic and prognostic 
significance of such aberrations would be facilitated (Hyytinen et al., 1994). FISH 
analyses in archival paraffin wax embedded tissues have been performed for colon, 
prostate, lung and breast cancer (Persons et al., 1994; Kim et al., 1993; Steiner et al., 
1993 Zitzelsberger et al., 1993; Arnoldus et al., 1991). Despite methodological and 
technical advances, there are limitations to obtaining signals by FISH in archival 
paraffin-embedded tissues as compared with fresh tumor tissues (Arnoldus et al., 1991). 
Although several methods have been used for analysis of archival paraffin-embedded 
tissues by FISH, they were only partially successful in many instances (Matsumura et al., 
1992; Hopman et al., 1991). The primary problems encountered are background tissue 
fluorescence and the relatively weak intensity of the signals obtained (Dhingra et al., 
1992). Furthermore, the formalin fixation period, sample pretreatments, protein digestion 
and denaturation have to be individually optimized for each sample.  
It would appear that for the FISH procedure to be successful in archival paraffin-
embedded breast cancer tissues stored for more than 12 months, sections have to undergo 
optimization of the pretreatment regime. For good results, pretreatment methods like 
protease digestion and NaSCN incubations have to be optimized for each individual case. 
Too short a digestion time yielded poor hybridization signals in most specimens, possibly 
because of inaccessibility of the probe to the cell nuclei. On the other hand, excessive 
protease digestion before hybridization may yield sufficient chromosome signals but with 
distortion of the nuclear morphology.  Despite the extensive variations in the pretreatment 
protocol, we were not able to get clear hybridization signals that could be evaluated in a 
reproducible and reliable way for all tissues that had been stored for more than 12 months. 
There was also a tendency for auto-fluorescence in the archival paraffin-embedded 
sections. 
As microwave oven tissue fixation, which has been used in many laboratories to 
shorten fixation time, was routinely used for fixation in many of our archived breast 
cancer specimens, the effect of this fixation method on the retrieval of FISH signals was 
also analyzed. The result shows that microwave oven fixation did not affect FISH signals. 
Targeting c-erbB2 by antibody (Herceptin) as a cancer therapeutic modality is of 
clinical importance. Integration of this assay into routine testing should help in 
rationalization of the most appropriate therapy for individuals with breast cancer. 
  
4.1.4 Concordance between c-erbB2 gene amplification and protein overexpression   
The observation of a good concordance between FISH and immunohistochemistry 
detection of c-erbB2 is in accord with those of other investigators (Couturier et al., 2000; 
Hoang et al., 2000; Vang et al., 2000). The concordance rate was as high as > 80% 
reported in literature (Perez et al., 2002; Ratcliffe et al., 1997). In this present study, 2+ 
IHC staining cases in the routine fixation protocol group showed no c-erbB2 (HER2/neu) 
gene amplification but in the other groups, 2+ IHC staining cases showed gene 
amplification. This is concordant with other studies done with larger samples. The c-erbB2 
(HER2/neu) gene was reportedly amplified between 12% to 35% of such (2+ IHC) cases 
(Perez et al., 2002; Kakar et al., 2000; Ridolfi et al., 2000). Possible reasons for the 
disparity in results obtained by FISH and IHC analyses include transcriptional or post-
transcriptional regulation for increased surface receptor expression in the absence of gene 
amplification (Hoang et al., 2000) and intrinsic variability of the IHC assay in terms of 
specimen processing and antigen retrieval (Wang et al., 2000).  Studies show that only 
distinct membranous immunostaining correlates with gene amplification and bears 
prognostic value in breast cancer and the cytoplasmic immunostaining is without such 
relevance (Lehr et al., 2001; Pegram and Slamon, 1999). Investigation in  one study, which 
compared the immunohistochemical and FISH methods for evaluation of c-erbB2 in breast 
cancer, found that both techniques were equally good  and therefore, recommended 
immunohistochemistry as a less time-consuming and expensive method for routine use in 
laboratories (Jacobs et al., 1999). However, in view of problems associated with IHC, 
particularly in the interpretation of results, FISH may provide additional useful information 
for classification of tumors as c-erbB2 positive or negative (Jimenez et al., 2000). 
 
4.2 C-erbB2 status and clinicopathological parameters  
4.2.1 C-erbB2 overexpression and hormonal receptor status 
 Estrogen and progesterone play major roles in normal breast development, in 
addition to breast carcinogenesis, by modifying the expression of a variety of genes 
through their receptors (Jin et al., 2000; Celentano et al., 1998). Estrogen and progesterone 
receptor status (both positive and negative) has been established as a predictive factor for 
breast cancer treatment, recurrence and prognosis (Li et al., 2003; Chu et al., 2001). 
Estrogen receptor (ER) and progesterone receptor (PR) status has also been validated as 
factors which predict response to hormonal therapy (Ring and Ellis, 2002; Yokota et al., 
1999). 
Reports have revealed an inverse relationship between the presence of ER and PR 
and c-erbB2 overexpression (Schroeder et al., 1997; Descotes et al., 1993; Tsuda et al., 
1993)). This is in agreement with findings in this present study, where c-erbB2 
overexpressed cases showed an inverse association with ER and PR positivity; ER 
positive tumors being more likely to be c-erbB2 negative than were ER negative tumors 
(74.1% versus 48.1%). A related finding of high levels of c-erbB2 being associated with 
ER and PR negativity was reported by Pous et al (2000). On the other hand, there have 
also been studies which do not show any correlation of hormone receptor positivity with 
c-erbB2 overexpression (Gullick et al., 1991).  
There are studies which suggest that ER-positive breast cancers that overexpress 
c-erbB2 may be less responsive to tamoxifen (a selective estrogen receptor modulator 
[SERM] which binds to ER and partially inhibits its activity, and is effective in the 
treatment and prevention of breast cancer), than breast cancer with low or no c-erbB2 
overexpression (Osborne et al., 2003; Benz et al., 1993). Differences found in c-erbB2 
amplification between steroid receptor positive and negative tumors could be helpful to 
define a specific subset of women in whom adjuvant therapy should be directed.  
Controversy exists between studies in relation to tamoxifen adjuvant therapy in cerbB2 
positive and negative groups. One shows that overall survival in the cerbB2 positive 
group treated with tamoxifen was significantly worse than the c-erbB2 negative group 
(Carlomagno et al., 1996). Another study showed no difference between c-erbB2 positive 
and negative groups (Constantino et al., 1994). A recent study showed that AIB-1, also 
called SRC-3, is an ER co-activator that plays a role in development of breast cancer. It 
has been found that high levels of activated AIB-1 could reduce the antagonist effects of 
tamoxifen especially in tumors that overexpress the c-erbB2 gene (Bouras et al., 2001).    
 The expression of c-erbB2 and hormone receptors are not always mutually 
exclusive but there are studies which showed that amplified c-erbB2 overexpression might 
precede the loss of hormone-dependence (Kurokawa et al., 2000; Schroeder at al., 1997). 
Overexpression of c-erbB2 confers anti-estrogen resistance to breast cancer. This has been 
well documented in multiple studies. A full-length cerbB2 cDNA transfected into ER 
positive MCF-7 human breast cancer cells causes loss of sensitivity to tamoxifen or 
estrogen dependence (Dowsett et al., 2001; Kurokawa et al., 2000; Miller et al., 1994). It is 
still unclear how c-erbB2 overexpression potentially mediates tamoxifen resistance in 
breast cancers (Chung et al., 2002). However, c-erbB2 overexpression results in activation 
of the Ras/MAPK signaling pathway in breast cancers (Tzahar et al., 1998). This leads to 
phosphorylation of Ser-118 in ER, leading to ligand-independent ER activation with loss 
of the inhibitory effect of tamoxifen on ER-mediated transcription (Kurokawa et al., 2000; 
Bunone et al., 1996). This shows that anti-Her2/neu therapy facilitates the inhibitory effect 
of tamoxifen on c-erbB2 overexpressing hormone dependent breast cancers (Witters et al., 
1997). There are also contradictory studies which do not support the hypothesis that 
overexpression of c-erbB2 is associated with tamoxifen unresponsiveness (Elledge et al., 
1998). 
4.2.2 C-erbB2 overexpression with histological grade and nuclear morphometry 
Histological grading is an essential component of the pathologic assessment of 
invasive breast carcinomas and its prognostic significance has been amply demonstrated 
(Richer et al., 1998; Periera et al., 1995; Ellis et al., 1991). Histological grade is regarded 
as a marker of cancer cell differentiation, and is determined by a combination of factors: 
tubule formation, nuclear pleomorphism and mitotic activity (Elston and Ellis, 1998). It is 
well known that cell differentiation is a complicated process, involving regulation of gene 
transcription, differential RNA processing and translation as well as intra- and inter-
cellular biomolecular regulation (Lin et al., 2003). Histologic grading of breast carcinoma 
is potentially of great clinical value in determining the prognosis.  Studies of the 
relationship between histologic grade per se and prognosis show a strong correlation. 
 C-erbB2 expression was found to correlate with histological grade in Caucasian 
and Japanese women with breast cancer (Hoff et al., 2002; Hung and Lau, 1999; Tsuda et 
al., 1993).  In a limited study of 167 Taiwanese cases, c-erbB2 overexpression was also 
correlated with the histological grade of infiltrative ductal breast carcinoma      (Tsai et 
al., 2001). In this current Singapore study, comprising a larger group of predominantly 
Chinese women, c-erbB2 overexpression was found in 26.1% of grade 1 carcinomas, 28 
% of grade 2 carcinomas and 43.3% of grade 3 carcinomas. This study also supports a 
positive correlation between c-erbB2 expression and histologic grade of breast cancer, 
with overexpression being less frequent in grade 1 and 2 than in grade 3 carcinomas. This 
is in concordance with many other studies (Hoff et al., 2002; Pous et al., 2000; Elstone 
and Ellis, 1991; Rilke et al., 1991; Tsuda et al., 1990). On the other hand, there are also 
studies which found no correlation between histologic grade and c-erbB2 overexpression 
(van de Vijver et al., 1988).    
Other than c-erbB2, progesterone hormone also has influence on histologic 
differentiation. PR negative tumors more often belong to the less differentiated, 
histological grade 3 invasive ductal breast cancers than the more differentiated, 
histological grade 2 tumors (Ruibal et al., 2001). This has been proven in an ‘in vivo’ 
study showing that progesterone hormone also has an impact over the histologic grade 
(Lin et al., 2003).  
Until now, the relationship between malignancy associated nuclear morphological 
features and functional properties of tumor cells remain unclear (Huang et al., 2000). 
Nuclear morphometry has been shown to be of prognostic utility in various cancers 
(Ikeguchi et al., 1998) as well as in invasive breast carcinoma (Tan et al., 2001; 
Kronqvist et al., 2000). In fact, increasing nuclear size has been postulated to be the result 
of accumulation of abnormal genetic material during carcinogenesis (Tan et al., 2001). In 
this study of 96 cases of breast carcinoma from Singapore women, there was no 
significant association between nuclear area and perimeter with c-erbB2 expression per 
se but tumors with positive c-erbB2 immunostaining had less round nuclei as compared 
to those defined as c-erbB2 negative. Variations in nuclear size and shape have been used 
as defining features of nuclear pleomorphism, a parameter in the designation of histologic 
grade. That c-erbB2 positive tumors comprised cancer cells with less round nuclei 
corroborates its link with poorer histologic grade. There are studies which postulate that 
oncogene amplification could be related to the morphology of a tumor (Poller et al., 1991; 
Cardiff et al., 1988), although our study did not show any association between nuclear 
size and overexpression of the c-erbB2 oncoprotein. Among c-erbB2 positive tumors, the 
nuclear size was significantly larger in histological grade 3 compared to histological 
grade 1 or 2 tumors, supporting the notion of increased amounts of abnormal genetic 
material in higher grade cancers. In addition, c-erbB2 positive tumors larger than 20 mm 
were associated with increased nuclear perimeter of the malignant cells. Though the 
nuclear size appeared larger for tumors which had lympho-vascular invasion and lymph 
node positivity, the results were not statistically significant. 
Quantitation of nuclear parameters is a powerful tool that may be an adjunct to 
other cytologic and molecular indicators of cancer diagnosis and prognosis (Pienta and 
Coffey, 1991). Nuclear morphometry of malignant tumors can reveal features that may 
otherwise escape subjective analysis of cellular morphology. Further studies with larger 
number of patients will be required to determine the importance of quantitative 
morphometry.  
4.2.3 C-erbB2 status and other clinicopathological parameters 
 The relationship between c-erbB2 overexpression and other clinicopathological 
parameters such as patient age, tumor size, axillary lymph node status, pathologic stage 
and lymphovascular invasion have remained controversial. One study found a statistically 
significant relationship between c-erbB2 and age at diagnosis, with a more pronounced c-
erbB2 overexpression in younger patients (Sjogren et al., 1998). Interestingly, in this 
present study, it was found that the frequency of c-erbB2 immuno-positivity decreased 
with older age at diagnosis. There were more c-erbB2 immuno-positive cases in the 
women aged ≤ 50 years as compared to those > 50 years i.e., 37.3% vs 33.2%. The 
findings are similar to that reported by Sjogren et al (1998). Most of the recent studies, as 
well as this present one, failed to attain any statistically significant difference between the 
age at diagnosis and c-erbB2 overexpression (Tsutsui et al., 2003; Pous et al., 2000; 
Bebenek et al., 1998; Sjogren et al., 1998; Chariyalertsak et al., 1996; Horiguchi et al., 
1994). There were variable results observed when cases were stratified as premenopausal 
versus post-menopausal groups. No significant difference was observed in a study 
between these groups (Yokota et al., 1999). In another study, statistically significantly 
worse OS was observed for c-erbB2 positive patients than negative ones (Sjogren et al., 
1998).  
 Tumor size by itself is one of the most powerful predictors of tumor behaviour in 
breast cancer (Fitzgibbons et al., 2000). However, its role as a prognostic marker 
combined with other prognostic factors is still not well investigated. The vast majority of 
breast cancers overexpressing c-erbB2, regardless of nodal status, are > 20mm in 
diameter (24.3 vs 20.7% in > 20mm and ≤ 20mm respectively). However, no statistical 
significance noted between c-erbB2 overexpression and tumor diameter in this present 
study.  Several studies have not reported any association between c-erbB2 overexpression 
and tumor size though several authors did (Korkolis et al., 2001; Pous et al., 2000; 
Ceccarelli et al., 1995; Rilke et al., 1991; van de Vijver et al., 1988). On the other hand, 
Giai et al (1994) and Rilke et al (1991) found that c-erbB2 overexpression was present 
more frequently in tumors larger than 20 mm when compared to smaller ones, while 
Helal et al (2000) observed a similar trend for T3 and T4 tumors.  
Axillary lymph node dissection is a routine staging procedure in the management 
of invasive breast cancer. The use of adjuvant systemic treatment is dependent on the 
axillary nodal status. Even though c-erbB2 overexpression by itself is potentially 
prognostic in breast cancer, uncertainty still remains regarding its prognostic effect with 
reference to axillary lymph node metastasis (Mittra et al., 1995). Most studies have found 
no association between c-erbB2 overexpression and axillary node status (Helal et al., 
2000; Sjogren et al., 1998; Barbati et al., 1997; Clarke and McGuire, 1991). Similarly, no 
statistically significant association was noted between c-erbB2 overexpression and nodal 
status in this present study. Positive nodes have been observed to be more often present 
when the primary tumor overexpresses c-erbB2 (Seshadri et al., 1993). The prognostic 
influence of c-erbB2 overexpression has been shown to increase arithmetically with 
increasing number of involved axillary lymph nodes (Mittra et al., 1995).  
In this present study, there was no significant association between c-erbB2 
overexpression and pathological staging, although breast cancer patients who showed c-
erbB2 positivity showed a trend towards more advanced stages; that is  42.9% of stage IV 
patients, 39.3% of stage III patients, 36.5% of stage II patients and 22.1% of stage I 
patients expressed c-erbB2 immunopositivity in their tumors. 
 C-erbB2 overexpression has been observed in about 40% to 60% of breast DCIS 
(Poller et al., 1991) as compared to about 10% to 40% only in invasive breast cancer. 
Plausible reasons for the relatively less frequent expression of c-erbB2 in invasive breast 
carcinoma include: overexpression of c-erbB2 diminishes during evolution from an in 
situ state to invasive breast carcinoma; or that the occurrence of invasive disease did not 
involve the c-erbB2 gene (Allred et al., 1992). The clinical usefulness of c-erbB2 
overexpression in DCIS is currently uncertain. As c-erbB2 plays an important role in 
tumor cell motility and distant spread (Bobrow et al., 1995), its expression may be useful 
in  predicting local recurrence in women who have undergone conservative resection of 
breast DCIS; or be indicative of the need to have  wider resection margins during 
excision of these tumors. 
 Lympho-vascular invasion is predictive of local failure and reduced overall 
survival (Pinder et al., 1994). In this present study, even though there was no statistically 
significant difference between c-erbB2 overexpression and lympho-vascular invasion, 
more c-erbB2 immuno-positive cases showed lympho-vascular invasion compared to c-
erbB2 negative cases (i.e.) 38% vs 33% respectively. This again implies c-erbB2 may 
play a role in cell motility in invasive disease.  
 
4.3 C-erbB2 status and biological markers 
Besides the conventional clinicopathological parameters, biological markers also 
play role in deciding the behavioral variability of invasive breast cancers. Recently, there 
has been much interest in the biological markers of breast cancer, as they may provide 
useful information on the clinical outcome and may also help in deciding the treatment 
modality. The biological markers evaluated in this study were Ki-67, iNOS and c-myc. 
 
4.3.1 C-erbB2 status and cell proliferation (Ki-67) 
 Increased cell proliferation or decreased cell death (apoptosis or programmed cell 
death) are essential processes vital to carcinogenesis.  There are many methods to 
evaluate cell proliferation in tissue samples; of all, Ki-67 immunostaining is a reliable, 
reproducible and easy method of estimating cell proliferative activity (Scholzen and 
gerdes, 2000). The Ki-67 index has been widely used in breast cancer research (Thor et 
al., 1999). There are studies which showed correlation between c-erbB2 overexpression 
and Ki-67 proliferation index (Rehman et al., 2000; Lee et al., 1992).  De Potter et al 
(1995) suggested that increased cell proliferation and enhanced cell motility are 
associated with overexpression of c-erbB2 in invasive breast cancers.   
In this present study, there was no statistically significant association between Ki-
67 proliferative activity and c-erbB2 overexpression, in keeping with studies which also 
did not find such a relationship (Val et al., 2002; Pavelic et al., 1992). It remains to be 
clarified why c-erbB2 overexpressed cancer cell clones are preferentially selected for 
outgrowth if they do not experience a proliferative advantage from this genomic 
alteration.  
 
4.3.2 C-erbB2 status and iNOS 
 Nitric oxide (NO) is a potentially toxic molecule, which has been implicated in a 
wide range of diverse patho-physiological processes. Inducible nitric oxide synthase 
(iNOS) has been the primary enzyme for the production of large amounts of NO in 
human tissues. Large amounts of NO formation have been shown to initiate apoptosis, 
helping to kill cancer cells and intracellular pathogens (Brune et al., 1998). iNOS 
expression has been widely studied in many cancers including breast cancer (Franchi et 
al., 2002; Kaguora et al., 2001; Vakkala et al., 2000; Klotz et al., 1998;). The c-erbB2 
overexpresion in relation to iNOS has not been much studied previously in breast 
cancers. This present study did not find any significant association between c-erbB2 
overexpression and iNOS expression, though there was a trend observed. Patients whose 
tumors stained positive for c-erbB2 protein were more likely to express iNOS compared 
to c-erbB2 negative patients (58.8% vs 42.6% respectively). One in vivo study showed a 
lowered NO producing breast cancer cell line to have reduced EGFR expression, which is 
a component of the c-erbB2 growth factor family (Martin et al., 1999). Further 
exploration is needed to assess the association between iNOS and c-erbB2 in invasive 
breast carcinoma. 
 
4.3.3 C-erbB2 status and c-myc  
The proto-oncogene c-myc encodes a transcription factor which plays a major 
role in early embryogenesis, as well as regulates normal cellular proliferation and 
differentiation. Aberrant c-myc expression is seen in many breast cancers (Pavelic et al., 
1991). In a normal cell, c-myc expression levels are under stringent control. C-myc is 
known to collaborate with other oncogenes to promote malignant transformation (Hynes 
et al., 2001). Hynes et al., in their study, further showed that deregulated c-erbB2 activity 
effectively stimulated cytoplasmic signaling pathways which in turn impinged on c-myc 
at various levels, causing its deregulated expression. C-myc amplification has been found 
to be a strong indicator of poor prognosis (Chrzan et al., 2001; Scorilas et al., 1999). 
In this present study, there was no significant association between c-erbB2 
overexpression and c-myc expression. This is concordant with that reported by Spandidos 
and co-workers (Spandidos et al., 1989).  The small sample size could have been a factor 
which influenced the statistical analysis of the correlation between c-erbB2 




4.3.4 Clinicopathological parameters and biological markers: Ki-67, iNOS and c-myc 
In this study, significant associations were obtained between proliferation marker 
Ki-67 and histologic subtype and histologic grade. Ki-67 has been positively correlated 
with mitotic counts, which is a component of histologic grade (Lee et al., 1992; Isola et 
al., 1990). Invasive ductal carcinoma subtype and histologic grade 3 tumors showed high 
proliferative activity in this study. Ki-67 has been shown to play a major role in cancer 
behavior and aggressiveness. It is also believed to predict DFS (Imamura et al., 1999). It 
has been documented that Ki-67 has good association with S-phase fraction (SPF) and 
aneuploidy, which reflect the biological behavior and aggressiveness of the cancer. These 
imply that determination of Ki-67 in invasive breast cancers may become useful in future.  
In this present study, iNOS expression is strongly positively correlated with the 
axillary lymph nodal status.  This is in accordance with another study, where they found a 
very strong correlation between the presence of NOS and axillary lymph node metastasis 
(Duenas-Gonzalez et al., 1997). This may be due to its major role in promoting 
angiogenesis. Vascularization is an absolute requirement for sustained tumor growth and 
its extent correlates positively with tumor metastasis (Tschugguel et al., 1999). Another 
report did not find any correlation between lymph node status and iNOS (Vakkala et al., 
2000).  The other clinicopathological parameters do not seem to produce any correlation 
with iNOS immunopositivity. Some studies reported a negative correlation between 
iNOS activity versus proliferation and grade, emphasized in one in vitro study, which 
showed inhibition of proliferation of human breast cancer cells by NO (Reveneau et al., 
1999). 
C-myc expression did not correlate with any of the clinicopathological 
parameters. Its true impact needs further study in larger samples.  
 
4.4 Follow up and survival analysis 
C-erbB2 gene amplification or protein overexpression independently predicts the 
DFS and OS in univariate and multivariate analysis. (Kobayashi et al., 2002; Dowsett et 
al., 2000; Gancberg et al., 2000;  Ross & Fletcher, 1998; Hawkins et al., 1993; Slamon et 
al., 1987). C-erbB2 overexpression has been reported to contribute to increased metastatic 
potential of cancer cells and to enhance malignancy (Ceccarelli et al., 1995). Upregulation 
of MMP-9 and MMP-2 protease activities by c-erbB2 causes increased invasiveness and 
VEGF expression thereby leading to a stronger angiogenic response and conferring 
apoptosis resistance in breast cancer cells (Yu and Hung, 2000; Tan et al., 1997). Slamon 
et al (1987) found that c-erbB2 gene amplification independently predicted OS and DFS 
in node-positive breast cancer patients. It has been reported that overexpression of c-
erbB2 protein is an unfavorable prognostic indicator in breast cancer, especially in 
patients with axillary nodal metastases. The influence of c-erbB2 on prognosis among 
node-negative patients appears uncertain (Agrup et al., 2000). A small series of mainland 
China breast cancers concluded that c-erbB2 overexpression was weakly associated with 
poor prognosis (Suo et al., 2001). In this present study, c-erbB2 status generated 
statistically significant differences in OS but not in DFS, though there was a trend 
observed for a shorter DFS in women with c-erbB2 positive breast tumors. Besides the 
significant difference in prognosis between patients with c-erbB2 positive and negative 
breast cancer in this study, a c-erbB2 positive status also adversely affected women with 
ER positive, node positive, histologic grade 1 and 2 tumors, and women aged over 50 
years at diagnosis. It has been suggested that c-erbB2 amplification promotes estrogen 
independence and tamoxifen resistance in ER positive tumors, leading to a poorer outlook 
for this group (Dowsett et al., 2001). In contrast, Elledge et al (1998) found no evidence 
of a poorer response to tamoxifen in ER positive metastatic breast cancer in spite of c-
erbB2 expression.  The latter study, however, defined c-erbB2 positivity when > 1% of 
cells stained immunohistochemically, and it is possible that differences in assignment of 
what constitutes c-erbB2 immunopositivity may have contributed to variability in the 
findings. Its adverse effect on histologic grade 1 and 2 tumors is not unexpected, and may 
be used to identify poor performers in this subset. The poorer prognosis of women older 
than 50 years with breast cancer that overexpressed c-erbB2 has been documented by 
Ferrero-Pous et al (2000), though they did not elaborate on the possible reasons for this 
observation. There was no prognostic significance of c-erbB2 overexpression in node 
negative or estrogen receptor negative patients and women ≤ 50 years at diagnosis.  
Multivariate analyses applied to the overall population identified c-erbB2 
overexpression as an independent prognostic factor when compared with ER and nodal 
status, and histologic grade; but lost its independent prognostic power when tumor size 
and pathologic stage were incorporated, confirming the latter two parameters as 






In conclusion, the salient findings in this study are: 
(1) C-erbB2 overexpression in invasive breast cancer in Singapore women has a 
similar pattern and trend as that reported in studies from other countries with 
mostly western populations. 
(2) C-erbB2 gene amplification by the FISH procedure can be compromised by 
the duration of fixation of tissues, storage of tissue blocks and influenced by 
pretreatment protocols. It is to be expected that in future, assessment of 
oncogene alterations in many tumor types will play a critical role in guiding 
diagnosis and treatment. Standardization of the assays to assess these gene 
alterations will be necessary before these assays can be used for routine 
clinical evaluation.  
(3) Strong correlation is found in between c-erbB2 gene amplification and protein 
overexpression. 
(4) C-erbB2 overexpression is strongly associated with poorly differentiated 
breast carcinoma and inversely correlated with hormone receptor status  
(5) Image cytometry analysis found correlation between nuclear roundness and 
histological grade and tumor size in c-erbB2 positive tumors. 
(6) Overexpression of c-erbB2 in invasive breast cancer is associated with poor 
overall survival.  
This study supports the hypothesis that c-erbB2 overexpression in breast tumors 









Fig. 37 Flow chart of significance of c-erbB2 overexpression/amplification in invasive 














4.6 Future study 
Although there is increasing information on the role of c-erbB2 as a prognostic 
factor and as a factor predicting response to systemic therapy, there is a pressing need to 
develop a comprehensive profile of the biologic and molecular characteristics of a tumor, 
rather than assessing one marker at a time. In future, the tools of molecular biology, such 
as microarray technology will permit such an assessment and will dramatically alter the 
manner in which breast cancers are classified and the way in which prognostic and 
predictive factors are determined.  However, the new molecular biology methods will 
need to be integrated with standard methods of pathologic evaluation.   
Expanding this study further by comparing c-erbB2 overexpression with other 
tumor markers like EGFR, bcl-2, pS2, Cathepsin D, p53, may help in establishing its 
significance in terms of prognosis. 
It is likely that in the near future, assessment of tumor suppressor genes and 
oncogene alterations in many tumor types will play a critical role in managing treatment 
modalities. Standardization of the assays to assess gene alterations will be necessary 
before these assays can be used for routine clinical evaluation. Assessment of c-erbB2 
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Citrate buffer – Antigen retrieval (pH 6.0) 
0.01M sodium citrate adjusted to pH 6 by 0.01M citric acid 
 
DAB reaction solution 
 
DAB     50mg  
TBS     100ml 
H2O2     33µl 
 
DAPI solution 
DAPI     0.1µg/ml in 2x SSC 
 
Harris Hematoxylin 
Hematoxylin    1g 
Absolute alcohol   10ml 
Ammonium alum   20g 
(or potassium alum) 
Mercuric oxide   0.5g 
dH2O     200ml 
 
Hydrogen peroxide/Methanol 
30% Hydrogen peroxide  100µl 
Methanol    5.9ml 
 
Protease solution (0.25mg/ml) 
Protease    25mg 
Protease buffer   50ml 
 
Silane coated slides 
2% solution of silane in absolute alcohol for 2 min 
 
Tris Buffered Saline (TBS) 
 
0.5M Tris stock solution, pH 7.4 100ml 
9% Sodium chloride    100ml 
Tween 20    0.5ml 





0.5% Tween 20 
Tween  20    0.5ml 
Wash buffer (2x SSC)   100ml 
 
10% Buffered formalin (neutral) 
37-40% formaldehyde solution  5 litres 
Water     45 litres 
Sodium phosphate monobasic 200g 
Sodium phosphate dibasic  325g 
 
0.2N HCl 
Concentrated Hcl (37%)  0.41ml 
DEPC water    25ml 
 
20x SSC (pH 7.4) 
Tri sodium citrate   88.2g 
Sodium chloride   175.4g 
Water     1 litre 
 
2x SSC 
20x SSC    100ml 
Distilled water    900ml 
 
 
 
